Washington, D.C. 20549

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2021 
Cerner Corporation
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
of Incorporation)
File Number)
(IRS Employer
Identification No.)
2800 Rock Creek Parkway64117
North Kansas City,Missouri
(Address of Principal Executive Offices)(Zip Code)
(816) 221-1024
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareCERNThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2021, Cerner Corporation ("Cerner") announced that it had released its financial results for the quarter ended September 30, 2021. A copy of the full text of the related press release, which is posted on the Investor Relations section of www.cerner.com under News & Events - Financial Releases, is furnished as Exhibit 99.1 hereto and incorporated by reference into this Item 2.02.

The information in Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise be subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.
d) Exhibits
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 29, 2021  By: /s/ Mark J. Erceg
   Mark J. Erceg, Executive Vice President
   and Chief Financial Officer

EX-99.1 2 a991pressreleasedatedoctob.htm EX-99.1 Document

Exhibit 99.1

Cerner Reports Third Quarter 2021 Results
Delivers Strong Results Across Key Metrics
GAAP Operating Margin and Diluted EPS Lower; Adjusted Operating Margin and Adjusted Diluted EPS Both
up Sharply vs. Year-Ago Quarter
Full-Year Guidance Increased

KANSAS CITY, Mo. - October 29, 2021 - Cerner Corporation (Nasdaq: CERN) today announced results for the 2021 third quarter that ended September 30, 2021.

"Cerner's strong third quarter and year-to-date results reflect good execution by our leadership team and our talented colleagues around the globe," said David Feinberg, M.D., President and CEO. "In the month I have been here, I have been impressed by the dedication and talent at Cerner, and my view has been reinforced that Cerner is well positioned to play an important role in improving healthcare and the clinician and patient experience."

2021 Third Quarter Highlights
Revenue of $1.468 billion, up 7% compared to $1.369 billion in the third quarter of 2020.
GAAP operating margin of 15.3%, down from 30.1% in the year-ago quarter, which included $217 million of gains on the sale of businesses.
Adjusted Operating Margin (non-GAAP) of 21.9%, up 150 basis points from 20.4% in year-ago quarter.
GAAP diluted EPS of $0.59, down 49% compared to $1.16 in year-ago quarter.
Adjusted Diluted EPS (non-GAAP) of $0.86 up 19% compared to $0.72 in year-ago quarter.
GAAP cash flow from operating activities of $435 million, up 14% compared to $382 million in year-ago quarter.
Free Cash Flow (non-GAAP) of $312 million, up 32% compared to $237 million in the year-ago quarter.

"During the third quarter, we delivered solid revenue growth, expanded Adjusted Operating Margin (non-GAAP) by 150 basis points and increased Adjusted Diluted EPS (non-GAAP) by nearly 20%," said Mark Erceg, Executive Vice President and Chief Financial Officer. "The organizational transformation and productivity measures implemented earlier this year and additional on-going product focus and cost control initiatives are strengthening our business. A clear focus on cash generation is also having a positive impact as evidenced by a 32% increase in Free Cash Flow (non-GAAP) for the quarter. The increase in Free Cash Flow (non-GAAP) and our strong balance sheet allowed us to repurchase $375 million of shares during the quarter, which brings our year-to-date purchases to $1.1 billion."

Future Period Guidance
Cerner currently expects:
Fourth quarter 2021 revenue to grow upper-mid-single digits compared to fourth quarter of 2020. This would bring full-year revenue growth to approximately 5%, consistent with prior guidance for mid-single-digit growth.
Fourth quarter 2021 Adjusted Diluted EPS growth of 10% to 13% over the fourth quarter of 2020. The high end of this range would bring full-year Adjusted Diluted EPS to $3.30, which compares to prior guidance of approximately $3.25.
Full year 2021 Free Cash Flow (non-GAAP) of more than $950 million, compared to prior guidance of approximately $900 million.
Total 2021 share repurchases of up to $1.5 billion.

Earnings Conference Call
Cerner will host an earnings conference call to provide additional detail on the Company's results and outlook at 8:00 a.m. CT on October 29, 2021. On the call, Cerner will discuss its results and answer questions from the investment community. The call may also include discussion of Cerner developments, and forward-looking and other material information about business and financial matters. The dial-in number for the conference call is (678) 509-7542; the passcode is Cerner. Cerner recommends joining the call 15 minutes early for registration.

An audio webcast will be available live and archived on the Investor Relations page of Cerner's website at investors.cerner.com (click News & Events, then Events & Presentations).

Information on Non-GAAP Measures and Non-GAAP Guidance
Adjusted Operating Margin, Adjusted Diluted EPS and Free Cash Flow are not recognized terms under GAAP. These non-GAAP financial measures should not be substituted for GAAP operating margin, GAAP diluted earnings per share, or GAAP cash flows from operating activities, respectively, as measures of Cerner's performance, but instead should be utilized as supplemental measures of financial performance in evaluating our business. Please see the accompanying schedule, titled "Reconciliation of GAAP Results to Non-GAAP Results," where our non-GAAP financial measures are defined and reconciled to the most comparable GAAP measures.

Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, items included in the accompanying schedule, titled "Reconciliation of GAAP Results to Non-GAAP Results." Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains or other items that may not directly correlate to the underlying performance of our business operations. The exact amounts of these adjustments are not currently determinable but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this future period non-GAAP guidance to the most comparable GAAP measures.

The future period guidance provided in this release reflects the Company's current view that the largest impact from the COVID-19 pandemic has already occurred. While the Company expects project and sales activity to continue improving, the COVID-19 pandemic could still cause unexpected impacts on future results. Therefore, the Company's forward-looking statements are subject to a higher-than-normal amount of risk.

About Cerner
Cerner's health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers a connected clinical and financial ecosystem to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.com, Cerner Perspectives, connect on Facebook, Instagram, LinkedIn, Twitter or join the discussion on Cerner's podcast Perspectives on Health & Tech. Nasdaq: CERN. Healthcare is too important to stay the same.

Investor Contact: Allan Kells, (816) 201-2445, akells@cerner.com
Media Contact: Stephanie Greenwood, (816) 201-2137, Stephanie.Greenwood@cerner.com
Cerner's Internet Home Page: www.cerner.com

All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements. These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The words "outlook", "guidance", "expects", "approximately", "would", "expectations", "future", "believe", "positioned", "plan", "growth", "think", "will", "opportunity", "goal", "anticipate" or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. For example, our forward-looking statements include statements regarding future period guidance and our share repurchase plans. Factors that

could cause or contribute to such differences include, but are not limited to the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect our financial condition, future bookings and results of operations; the possibility of interruption at our data centers or client support facilities, or those of third parties with whom we have contracted (such as public cloud providers), that could expose us to significant costs and reputational harm; the possibility of increased expenses, exposure to legal claims and regulatory actions and reputational harm associated with a cyberattack or other breach in our IT security or the IT security of third parties on which we rely; potential claims for system errors and warranties or significant costs and reputational harm related to product and service-related liabilities; material adverse resolution of legal proceedings or other claims or reputational harm stemming from negative publicity related to such claims or legal proceedings; risks associated with our global operations, including without limitation greater difficulty in collecting accounts receivable; significant competition and our ability to anticipate or respond quickly to market changes, changing technologies and evolving pricing and deployment methods and to bring competitive new solutions, devices, features and services to market in a timely fashion; risks inherent with business acquisitions, strategic investments, collaborations and the failure to achieve projected synergies, or divestitures; managing growth in the new markets in which we offer solutions, healthcare devices or services; long sales cycles for our solutions and services; risks related to our dependence on strategic relationships and third party suppliers, including any impact to such supplier's business resulting from the COVID-19 pandemic; risks associated with the loss or recruitment and retention of key personnel, or the failure to successfully develop and execute succession planning to assure transitions of key associates and their knowledge, relationships and expertise; inability to achieve expected operating efficiencies and sustain or improve operating expense reductions or business disruptions or adverse tax consequences associated with restructuring, realignment and costs reduction activities; changing political, economic and regulatory influences, which could impact the purchasing practices and operations of our clients and increase costs to deliver compliant solutions and services; non-compliance with laws, regulations or certain industry initiatives or failure to deliver solutions or services that enable our clients to comply with laws or regulations applicable to their businesses; risks inherent in contracting with government clients, including without limitation, complying with strict compliance and disclosure obligations, navigating complex procurement rules and processes, and defending against bid protests; volatility and disruption resulting from global economic or market conditions, including the impact from the COVID-19 pandemic; risks associated with our outstanding and future indebtedness, such as compliance with restrictive covenants, which may limit our flexibility to operate our business; risk that our capital allocation strategy will not be fully implemented or enhance long-term shareholder value; changes in tax laws, regulations or guidance that could adversely affect our tax position and/or challenges to our tax positions in the U.S. and non-U.S. countries; the potential for losses resulting from asset impairment charges; potential variations in our sales forecasts compared to actual sales; risks that our revenue growth may be lower than anticipated and/or that the mix of revenue shifts to low margin revenue; variations in our quarterly operating results; and risks associated with fluctuations in foreign currency exchange rates. Additional discussion of these and other risks, uncertainties and factors affecting Cerner's business is contained in Cerner's filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Except as required by law, Cerner undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes in our business, results of operations or financial condition over time.

For the three and nine months ended September 30, 2021 and September 30, 2020
(In thousands, except per share data) Three Months EndedNine Months Ended
Revenues$1,467,976 $1,368,673 $4,312,509 $4,110,763 
Costs of revenue251,111 231,889 743,092 698,268 
Margin1,216,865 1,136,784 3,569,417 3,412,495 
Operating expenses
Sales and client service651,010 625,402 2,004,263 1,907,138 
Software development202,663 186,826 636,590 551,101 
General and administrative121,395 116,816 390,067 391,000 
Amortization of acquisition-related intangibles16,874 12,789 45,956 43,031 
Total operating expenses991,942 941,833 3,076,876 2,892,270 
Gain on sale of businesses— 216,869 — 216,869 
Operating earnings224,923 411,820 492,541 737,094 
Other income (loss), net(5,070)48,020 (5,542)78,247 
Earnings before income taxes219,853 459,840 486,999 815,341 
Income taxes(44,058)(103,164)(106,245)(176,758)
Net earnings$175,795 $356,676 $380,754 $638,583 
Basic earnings per share$0.59 $1.17 $1.27 $2.08 
Basic weighted average shares outstanding296,202 305,759 300,526 306,759 
Diluted earnings per share$0.59 $1.16 $1.25 $2.07 
Diluted weighted average shares outstanding298,714 308,366 303,423 309,124 

Note 1: Our revenues by business model for the three and nine months ended September 30, 2021 and September 30, 2020 were as follows:
(In thousands) Three Months EndedNine Months Ended
Licensed software$199,179 $171,694 $535,956 $481,888 
Technology resale37,584 47,113 140,116 140,717 
Subscriptions91,771 93,407 290,020 279,844 
Professional services551,748 479,895 1,583,248 1,452,323 
Managed services323,132 311,844 961,285 928,356 
Support and maintenance257,025 259,978 780,024 807,695 
Reimbursed travel7,537 4,742 21,860 19,940 
Total revenues$1,467,976 $1,368,673 $4,312,509 $4,110,763 

For the three and nine months ended September 30, 2021 and September 30, 2020


(In thousands) Three Months EndedNine Months Ended
Operating expenses (GAAP)$991,942 $941,833 $3,076,876 $2,892,270 
Share-based compensation expense(55,666)(38,137)(157,592)(111,724)
Acquisition-related amortization(16,874)(12,789)(45,956)(43,031)
Organizational restructuring and other expense(23,472)(31,798)(219,538)(118,531)
COVID-19 related expense(454)(1,069)(3,103)(4,212)
Adjusted Operating Expenses (non-GAAP)$895,476 $858,040 $2,650,687 $2,614,772 


(In thousands) Three Months EndedNine Months Ended
Operating earnings (GAAP)$224,923 $411,820 $492,541 $737,094 
Share-based compensation expense55,666 38,137 157,592 111,724 
Acquisition-related amortization16,874 12,789 45,956 43,031 
Organizational restructuring and other expense23,472 31,798 219,538 118,531 
COVID-19 related expense454 1,069 3,103 4,212 
Gain on sale of businesses— (216,869)— (216,869)
Adjusted Operating Earnings (non-GAAP)$321,389 $278,744 $918,730 $797,723 
Operating Margin (GAAP)15.32 %30.09 %11.42 %17.93 %
Adjusted Operating Margin (non-GAAP)21.89 %20.37 %21.30 %19.41 %


(In thousands, except per share data) Three Months EndedNine Months Ended
Net earnings (GAAP)$175,795 $356,676 $380,754 $638,583 
Pre-tax adjustments for Adjusted Net Earnings:
Share-based compensation expense55,666 38,137 157,592 111,724 
Acquisition-related amortization16,874 12,789 45,956 43,031 
Organizational restructuring and other expense23,472 31,798 219,538 118,531 
COVID-19 related expense454 1,069 3,103 4,212 
Investment gains— (49,424)— (75,834)
Gain on sale of businesses— (216,869)— (216,869)
After-tax adjustments for Adjusted Net Earnings:
Income tax effect of pre-tax adjustments(19,331)46,305 (83,499)13,502 
Share-based compensation permanent tax items3,260 1,517 4,112 (2,524)
Valuation allowance on deferred tax assets— — 6,153 3,318 
Adjusted Net Earnings (non-GAAP)$256,190 $221,998 $733,709 $637,674 
Diluted weighted average shares outstanding298,714 308,366 303,423 309,124 
Diluted earnings per share (GAAP)$0.59 $1.16 $1.25 $2.07 
Adjusted Diluted Earnings Per Share (non-GAAP)$0.86 $0.72 $2.42 $2.06 


(In thousands) Three Months EndedNine Months Ended
Cash flows from operating activities (GAAP)$434,821 $381,949 $1,254,390 $924,045 
Capital purchases(47,532)(71,757)(246,813)(238,053)
Capitalized software development costs(75,569)(73,317)(242,677)(224,710)
Free Cash Flow (non-GAAP)$311,720 $236,875 $764,900 $461,282 
Cash flows from investing activities (GAAP)$205,259 $(211,779)$(705,560)$(596,825)
Cash flows from financing activities (GAAP)$(417,699)$(22,958)$(693,077)$(345,527)

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America ("GAAP"). However, we supplement our GAAP results with certain non-GAAP financial measures, which we believe enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational and economic performance. These non-GAAP financial measures are not meant to be considered in isolation, as a substitute for, or superior to GAAP results and investors should be aware that non-GAAP measures have inherent limitations and should be read only in conjunction with Cerner's consolidated financial statements prepared in accordance with GAAP. These non-GAAP measures may also be different from similar non-GAAP financial measures used by other companies and may not be comparable to similarly titled captions of other companies due to potential inconsistencies in the method of calculations. We provide the measures of Adjusted Operating Expenses, Adjusted Operating Earnings, Adjusted Operating Margin, Adjusted Net Earnings and Adjusted Diluted Earnings Per Share as such measures are used by management, along with GAAP results, to analyze Cerner's business, make strategic decisions, assess long-term trends on a comparable basis, and for management compensation purposes. We provide the measure of Free Cash Flow as such measure takes into account certain capital expenditures necessary to operate our business. Free Cash Flow is used

by management, along with GAAP results, to analyze our earnings quality and overall cash generation of the business, and for management compensation purposes.

We calculate each of our non-GAAP financial measures as follows:

Adjusted Operating Expenses - Consists of GAAP operating expenses adjusted for: (i) share-based compensation expense, (ii) acquisition-related amortization, (iii) organizational restructuring and other expense, and (iv) COVID-19 related expense.

Adjusted Operating Earnings - Consists of GAAP operating earnings adjusted for: (i) share-based compensation expense, (ii) acquisition-related amortization, (iii) organizational restructuring and other expense, (iv) COVID-19 related expense, and (v) gain on sales of businesses.

Adjusted Operating Margin - Consists of Adjusted Operating Earnings, as defined above, divided by revenues, in the applicable period; the result presented as a percentage.

Adjusted Net Earnings - Consists of GAAP net earnings adjusted for: (i) share-based compensation expense, (ii) acquisition-related amortization, (iii) organizational restructuring and other expense, (iv) COVID-19 related expense, (v) investment gains, (vi) gain on sale of businesses, (vii) the income tax effect of the aforementioned items, (viii) share-based compensation permanent tax items, and (ix) valuation allowance on deferred tax assets.

Adjusted Diluted Earnings Per Share - Consists of Adjusted Net Earnings, as defined above, divided by diluted weighted average shares outstanding, in the applicable period.

Free Cash Flow - Consists of GAAP cash flows from operating activities, less capital purchases and capitalized software development costs.

Adjustments included in the calculations above are described below:

Share-based compensation expense - Non-cash expense arising from our equity compensation and stock purchase plans available to our associates and directors. We exclude share-based compensation expense as we believe the amount of such non-cash expenses in any specific period may not directly correlate to the underlying performance of our business operations. Share-based compensation expense is included in our Condensed Consolidated Statements of Operations as follows:

(In thousands) Three Months EndedNine Months Ended
Sales and client service$23,040 $20,556 $70,262 $55,537 
Software development5,538 5,460 18,118 15,242 
General and administrative27,088 12,121 69,212 40,945 
Total share-based compensation expense$55,666 $38,137 $157,592 $111,724 

Acquisition-related amortization - Non-cash expense consisting of the amortization of customer relationships, acquired technology, and trade name intangible assets recorded in connection with our acquisitions of the Health Services business in February 2015, AbleVets in October 2019, and all subsequent acquisitions. We exclude acquisition-related amortization as we believe the amount of such non-cash expenses in any specific period may not directly correlate to the underlying performance of our business operations. Such amount is included in our Condensed Consolidated Statements of Operations in the caption "Amortization of acquisition-related intangibles."

Organizational restructuring and other expense - Consists of certain charges incurred in connection with our operational improvement initiatives. Expenses in connection with these efforts may include, but are not limited to, consultant and other professional services fees, employee separation costs, contract termination costs, asset impairment charges, and other such related expenses. We exclude organizational restructuring and other expense as we believe the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations. Organizational restructuring and other expense is included in our Condensed Consolidated Statements of Operations as follows:

(In thousands) Three Months EndedNine Months Ended
Sales and client service$— $— $75,191 $933 
Software development2,143 — 47,309 — 
General and administrative21,329 31,798 97,038 117,598 
Total organizational restructuring and other expense$23,472 $31,798 $219,538 $118,531 

Sales and client service includes a $68.159 million pre-tax charge in the second quarter of 2021 to reduce the carrying amount of certain held for sale real estate assets to fair value, less estimated costs to sell. Software development includes pre-tax charges in the second and third quarters of 2021 of $45.166 million and $1.928 million, respectively, to reduce the carrying amount of certain capitalized software development costs to estimated net realizable value.

COVID-19 related expense - Consists of certain charges incurred that we can clearly and objectively attribute to the impact of the ongoing Coronavirus disease pandemic ("COVID-19"). These charges include expenses incurred related to trade shows for which we withdrew our participation and expenses associated with incremental cleaning and sanitation efforts for facility space that may have been exposed to the virus. We exclude COVID-19 related expense as we believe the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations. COVID-19 related expense is included in our Condensed Consolidated Statements of Operations as follows:

(In thousands)Three Months EndedNine Months Ended
Sales and client service$323 $444 $1,320 $2,919 
Software development(5)70 268 70 
General and administrative136 555 1,515 1,223 
Total COVID-19 related expense$454 $1,069 $3,103 $4,212 

Investment gains - Consists primarily of gains recognized upon the disposition of equity investments, which were accounted for in accordance with Accounting Standards Codification Topic 321, Investments-Equity Securities. We have excluded these gains as we believe the amount of such gains do not directly correlate to the underlying performance of our business operations in the periods they were recorded. Such gains are included in our Condensed Consolidated Statements of Operations in the caption "Other income (loss), net."

Gain on sale of businesses - Consists of gains recognized upon the disposition of certain of our business operations, primarily conducted in Germany and Spain, in July 2020 and certain of our commercial revenue cycle outsourcing business operations in August 2020. We have excluded these gains as we believe the amount of such gains do not directly correlate to the underlying performance of our business operations in the periods they were recorded. Such gains are included in our Condensed Consolidated Statements of Operations in the caption "Gain on sale of businesses."

Income tax effect of pre-tax adjustments - The GAAP effective income tax rate for the applicable quarterly period, adjusted for the impact of valuation allowances on deferred tax assets of $6.153 million and $3.318 million recorded in the second quarter of 2021 and first quarter of 2020, respectively, as describe below; and the impact of $53.351 million of taxes recognized in the third quarter of 2020 on the gain on sale of businesses described above, is applied to pre-tax adjustments for Adjusted Net Earnings.

Share-based compensation permanent tax items - Consists of permanent items impacting the Company's income tax provision related to our share-based compensation arrangements, including net excess tax benefits recognized upon the exercise of stock options and the vesting of restricted share and share unit awards. We exclude such items as we believe the amount of such items

in any specific period may not directly correlate to the underlying performance of our business operations. Such amount is included in our Condensed Consolidated Statements of Operations in the caption "Income taxes."

Valuation allowance on deferred tax assets - Consists of a valuation allowance recorded against certain deferred tax assets where certain strategic decisions associated with our operational improvement initiatives have made it more likely than not that such deferred tax assets will not be realized. We have excluded this charge as we believe the amount of such expense does not directly correlate to the underlying performance of our business operations in the period recorded. Such amount is included in our Condensed Consolidated Statements of Operations in the caption "Income taxes."

As of September 30, 2021 and December 31, 2020
(In thousands)20212020
Current assets:
Cash and cash equivalents$459,540 $615,615 
Short-term investments322,634 442,473 
Receivables, net1,219,849 1,168,712 
Inventory25,389 23,027 
Prepaid expenses and other412,744 401,160 
Total current assets2,440,156 2,650,987 
Property and equipment, net1,717,630 1,804,083 
Right-of-use assets89,619 104,536 
Software development costs, net1,008,440 1,009,349 
Goodwill1,126,843 914,520 
Intangible assets, net476,067 329,249 
Long-term investments488,454 510,220 
Other assets195,951 198,152 
Total assets$7,543,160 $7,521,096 
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable$311,196 $235,755 
Current installments of long-term debt225,000 — 
Deferred revenue438,063 393,293 
Accrued payroll and tax withholdings344,879 309,814 
Other current liabilities232,187 229,764 
Total current liabilities1,551,325 1,168,626 
Long-term debt1,611,205 1,336,069 
Deferred income taxes389,843 376,035 
Other liabilities150,884 157,799 
Total liabilities3,703,257 3,038,529 
Shareholders' Equity:
Common stock3,785 3,732 
Additional paid-in capital2,598,853 2,288,806 
Retained earnings6,656,679 6,475,551 
Treasury stock(5,289,718)(4,164,718)
Accumulated other comprehensive loss, net(129,696)(120,804)
Total shareholders' equity3,839,903 4,482,567 
Total liabilities and shareholders' equity$7,543,160 $7,521,096 

For the three and nine months ended September 30, 2021 and September 30, 2020
Three Months EndedNine Months Ended
(In thousands)2021202020212020
Net earnings$175,795 $356,676 $380,754 $638,583 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization181,249 175,046 535,816 518,987 
Share-based compensation expense55,274 37,920 157,165 110,500 
Provision for deferred income taxes350 8,670 3,582 21,554 
Gain on sale of businesses— (216,869)— (216,869)
Investment gains— (49,424)— (75,834)
Asset impairments1,927 — 117,739 — 
Changes in assets and liabilities (net of businesses acquired):
Receivables, net7,803 (30,269)(33,948)(78,695)
Inventory(5,228)2,697 (2,360)8,206 
Prepaid expenses and other(12,005)(233)(2,091)(36,664)
Accounts payable(26,621)(29,097)27,467 (60,808)
Accrued income taxes1,515 6,647 13,100 33,005 
Deferred revenue11,729 34,066 11,053 (32,071)
Other accrued liabilities43,033 86,119 46,113 94,151 
Net cash provided by operating activities434,821 381,949 1,254,390 924,045 
Capital purchases(47,532)(71,757)(246,813)(238,053)
Capitalized software development costs(75,569)(73,317)(242,677)(224,710)
Purchases of investments(48,704)(419,421)(607,390)(511,378)
Sales and maturities of investments373,191 132,287 753,347 213,309 
Purchase of other intangibles(7,166)(9,042)(23,197)(29,698)
Acquisition of businesses, net of cash acquired1,690 — (348,179)(35,766)
Sale of businesses— 229,471 — 229,471 
Disposition of assets held for sale9,349 — 9,349 — 
Net cash provided by (used) in investing activities205,259 (211,779)(705,560)(596,825)
Long-term debt issuance— — 500,000 300,000 
Repayment of long-term debt— (2,500)— (2,500)
Proceeds from exercise of stock options59,677 45,772 214,577 202,680 
Payments to taxing authorities in connection with shares directly withheld from associates(25,813)(8,406)(62,159)(22,623)
Treasury stock purchases(375,000)— (1,125,000)(650,000)
Dividends paid(66,794)(55,176)(202,054)(166,277)
Net cash used in financing activities(417,699)(22,958)(693,077)(345,527)
Effect of exchange rate changes on cash and cash equivalents(9,245)2,047 (11,828)(4,382)
Net increase (decrease) in cash and cash equivalents213,136 149,259 (156,075)(22,689)
Cash and cash equivalents at beginning of period246,404 269,895 615,615 441,843 
Cash and cash equivalents at end of period$459,540 $419,154 $459,540 $419,154 

EX-101.SCH 3 cern-20211029.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Statement of Financial Position link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Statement of Income link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 cern-20211029_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 cern-20211029_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Entity Emerging Growth Company Entity Emerging Growth Company Entity [Domain] Entity [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Information [Line Items] Entity Information [Line Items] Local Phone Number Local Phone Number Legal Entity [Axis] Legal Entity [Axis] Cover [Abstract] Cover [Abstract] Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Document Type Document Type Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 6 cern-20211029_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 cern-20211029_htm.xml IDEA: XBRL DOCUMENT 0000804753 2021-10-29 2021-10-29 0000804753 false 8-K 2021-10-29 Cerner Corporation DE 0-15386 43-1196944 2800 Rock Creek Parkway 64117 North Kansas City, MO 816 221-1024 false false false false Common Stock, $0.01 par value per share CERN NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Document
Oct. 29, 2021
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Oct. 29, 2021
Entity Registrant Name Cerner Corporation
Entity Incorporation, State or Country Code DE
Entity File Number 0-15386
Entity Tax Identification Number 43-1196944
Entity Address, Address Line One 2800 Rock Creek Parkway
Entity Address, City or Town North Kansas City,
Entity Address, State or Province MO
Entity Address, Postal Zip Code 64117
City Area Code 816
Local Phone Number 221-1024
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol CERN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000804753
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Document Sheet http://www.cerner.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports cern-20211029.htm a991pressreleasedatedoctob.htm cern-20211029.xsd cern-20211029_def.xml cern-20211029_lab.xml cern-20211029_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cern-20211029.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "cern-20211029_def.xml" ] }, "inline": { "local": [ "cern-20211029.htm" ] }, "labelLink": { "local": [ "cern-20211029_lab.xml" ] }, "presentationLink": { "local": [ "cern-20211029_pre.xml" ] }, "schema": { "local": [ "cern-20211029.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cern", "nsuri": "http://www.cerner.com/20211029", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cern-20211029.htm", "contextRef": "i79152634913d4fbb8dba1a347432e33d_D20211029-20211029", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Document", "role": "http://www.cerner.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cern-20211029.htm", "contextRef": "i79152634913d4fbb8dba1a347432e33d_D20211029-20211029", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cerner.com/role/CoverDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000804753-21-000050-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000804753-21-000050-xbrl.zip M4$L#!!0 ( $(\75/")?Q4+$T "]>!0 > 83DY,7!R97-S<3(";N( R22S,CBY9(H%<3IX]S_+K_[J^ MOWKZGR\W9) . _+EK]\_W5Z1'\[?O_^7?O7^_?73-?GSZ?,G8K04E3S%3ICX MJ1^%3O#^_(]#&>^#*$I8RTN]'W[[ M%3^!G\SQ?OO_?OU?Y^?D.G+'0Q:FQ(V9DS*/C!,_[)-_>2SY2L[/LZ>NHM$D M]ON#E&B*II)_1?%7_]D1WZ=^&K#?\G%^?2_^_O4]G^37;N1-?OO5\Y^)[_W7 M#[YGFQ93.K:M&YZA>(;-'+/;[;H]Q>G:NFG]_RHL\CT\+MY)TDG _NN'H1^> M#QC.?V%H+?"\=7*B*\O,/"X^F[%MZ[@1^/[S@"X9O>U&8PD)B&%C\ M*L9_-<\9^L'DXA]/_I EY(Z]D(=HZ(3_H F< MSWG"8K\G'DS\_[ +585U\S]?Q%XL&"?P0Y;O3=5P-S??!G[73XEMM]3%%;]I MFZM?N3:#\;(/6Z^/))/T0N+?_G1M#^0 M2^_?XP0_7_G2]-OYMW^/T@&I(6S&(_(X<.)1,"'/28O\#W/B\\M^E.-US7:D MP8X^CH/@'/=!_AC[GA.ZC-R&*"82.*I7^]G$@([.2/GZ__OR[O'RD5S=/OT/ M)9^C%CDG]VX:=9')V%0PFO/I1@Z[PM40SACA510#)W10GI.S.R?QG+^!?#H? MR-7-P]T[DD:>,P&"":,QG(%'XHRE]**8I ,F-I)R)OIWQD33@9,2%GKP]",; MI6R(F]85L>E6$5Q$RO1[DUWERN)KQX;G+S_JQ@81]8^Z8GT=W0J)Q3 )09H"K#_P129DSY,/@YT!+ M2+0>@2W",_TQ;,:)X: \?C3] -"-\F61Q/&!TSG/\/,C\T,XD3Z@9>NZ1,#2#KG<.>]&:1H-+W3 IQ+0=K4^Q EX40OZ$[X. M\)&D)/[$%[9>#H\V#FC"&:90\C+PW0%\[09CU%!^TE2+ M##/<@N'ZCA\F)!)O)R"W\,,N^B50P"42PPZ*86M-ME*Q["R,PG-$_G>?PW,F;&?-E,Z:?E)9I9XS) ML%_)-+4M<:0\_G)=$3Q99"V ,ITVYRS+^**T+$WB2SD\Q762 >D%T8O@[S,% MR'%3_QE,4E:NG82(8^AFKL4(T60L(9#>T:9JCL2C8^/1QY@Q(XNJHM((ZN+2&.IEOSB+-*J6ZX3^]Z'/OI8<[@I=?QLQ=R+=R6NE$OU4_M3UO?+:8G&$$(XGF( >^O.\ M\P\F^TIN8I?U*;D1'L9G1O[INVS9 SCP68]\]$,G='TG(/>]'CP49U[!)X!" M%/>=T/^/(^Z 28H7PKTH'LXPH7!9XAI][BR& MG2)"\?>0>+)184?]"*&4C45ZD3L6T'"C)(4?81I' 8 &WG!P,^C\9.AX96$? M#BO$E]%-FEMO+4(NB1O@7&(L6"SG[7T6LLP##HMQ@B1"WR;G\)G3$2 %BP=^ M3YR$L&<$EBN\G0ZGF/Q\D$*6:'WN;'*?>4XVA" TB[V;^WPSOW+7"?B=2#)@ M#!85P-/\^AQ)-F:C<>P.<,B?=,NLDN[N(7"9]IP5&=CYCD MVFONCSDY?^G'<0K(3+[ VY$WO9RJ-"N;O_=VQS'01PK\ 7W>;IJ(RQXI_O>R MA'7B'^@I'4R]E=SEG@L*H">4%2![02Z<#WWO'&-@ I L?M\']C\OC'N+X^1> M3^0C>$D2C0-/4##IX?4I9ZN+ @E'<4; 4K_YP*X9H('Y,T5>"@(G10GPXL-# M(\#MF/3SBU?D6[.%G?.%9>/57V_,Y'R9B -+V %Q5FH V>FB/U3Y&0]9U7\F MT3,3 F<#WC R@$7@=2U^S*4QB/,^6X--*R?G]D4+;WB%$,E0ELN*)52".1;1 M#U[43(E%A\4B.#ZA8W$$6J]DP.D,HQC57"MV<\I?@@<#%IU0V,RIPK8O76W/>MS)#K046YI'.5S$+.!F MS=IHTVQJ9?:*TP4C%-ARD0#5A7BOM1&JXN<@GA%MGYUWP5[Y>N[TX/T+)WAQ M)LGB+ 4B9HL'QI9Q8$>/NG7BD-M=5U'88S$:E\"@@Z#25L5\$-D+\!8R0+,< M! ?+=^/.=N/";H3HB-!ZGC?T/98Z?I!?N5ZAG DG_TBFL5'"\DV#*/J*$40= M;K" @'%:PQ:Y>L(7ER/K0+.Y%\/AO)3,K]+S$[#]$^*GBU, $%[@F;_'+,&% M99=Y*3?0G^$S$:<>#8?CT$\GF>[$MS7$0"1T&F27ROD4FZ!'AY$(QPF M$?%/H%:_.+%WCCOCS@;<*$P(RC;(T1A]+SP>*O>K= $*4V>&&&'JI(%GX)4D M6Y8''X'4).&8Q][E?H?E\P!=[ZQM==X14['/+=/01-PL/CIRDL2-8"_PC-@ M#)WM)&8(!M 8$_+OR ]S3P(?4D5W0P@L*"'""X5SQZP/UH7PL+1V=7Y^!'7T M*R >^0-@X[OD=X#6.IS5"N%LJ5&7A:*+:^DKO004'7M^1%Y8UW625)!;%VC] M&>C;Z8))BZY206R@HL#O7D[UMYS$(@S+#QQ!?BAI9N3S#XP![(*88\@#_.SQ MI.4*W 2$)&=NX+M?<3<)NBH['\C-LR V= 9F?V3?H,<3_A13O=N[__J5J"E) MKMS.L0_X_UVFZ)//N4<6SV+Z:2U\60+5UOG2Z6H#%;>Y9/6@KAQ&*6=F_1#F M!LN&Q<.$C,'8B D"1##3!)_+(#3';W,()@-N)^-0@.K)N MP2?G$R/E61DQ1 MLA"J,!67\)A0XBG)7YU>/2;K[QXIBC%TY0%!!1.*'NKIZN;I!U[EV G3$&, M(!4!H!POWP(L?YSZ 0<%C)&,1YFW?GZ[,. ,"',CHO.:/3O!6*QNR>W^)> . M[H0Q3NV.ZPHICX\F[H!YXP#6Q'.W/''-\ #' I,$?H:\/0&//*$%-(DIVF:? M97<=+QB=S.??=&IX^AZ#+W"OH<>Q *<3]JT(>^9W#&CTY8Y'5' "?^@+QDRS,:>Q>MGUXT'01]QC$/(XAH7-[PT7B4*LUP,2 M$W<^8%Z'?;S/0JXJ+JE 71H/1T)R(4+]>^SU,*$>Z>#X.C M9Q_ S8U'EB,SYVD!A]<\S6:G,U4I9R>4Z9'L&[_R&D9CA 3W#R(_G =/SD=G M]PJ@SP,C!9I#LD$^DT$P >3V>X 980K#WZ:H6N)66"_*QAC%R-5<_N*&=TAHY@)OAVEIV2+!EHV9&+ M) Z.B?A]P'$WS>]+IU;4U?T_;Z_/59OP^_ A:/*8]^$$,8B@"8E"'LXTW'-/^#KIG8Y?(.3@&HTG7& M"1*(F ,WS]?-+X$).>@^(3]4OR$L6! M]X*<.$OK$EH2S]GGR#Z<9;=U&?HA"$^YXEH!Z (P((BY/'1#.%!\5*(>9KHW MYJHY0>8O\,,P>LY4@,SG /+53_ V-$_?XM)WZ'!JG)HKFD M1#ROU)EDZ21#]EJS^"[UH7):QSI'1.;?N8)'@=/PDRLU:)9@-\ M/NNH[7=$4]1SS3!,H,2O^/DO/[:-#W,>IO)3R_G:/P,7=JH#R<>4C4"7\4&% MCAD+7Z+(6P"HJEMT]E!K^M 2="L"W"DWNL7KL9"EY,]HR,@7X-Z+D5)EP!H+ M[&R V*&X1>E,1GEC$0F@\7E5/+=K>++ZU+KAEHL7+9K0*$?9-S< TQB]:F1F M3\, P,BXT.]Q0P&#IX3/;X,9T,IID[P,V@)+-I_ O>Q_YM&Z*SH_,N)K780"@XG(0E8:I(EQ&V14C_YV*CW++>/ZS:=3D[*.% MX)?Y+W@(U>N7Q0'.?RX.9?X3?N;/"Q_-RA\L? I2;&'-/!!L_A- ^7!A6W@O M,_]WQ-5)?JVY,%+D+#PV\U )5UEVJ1BR_M37)]Q#'*B@2CJQG^$J=_.@MRD& ME +*=^+\K 0JUGB$HL^^9@7#GEOJP-])7?SLY]%,/: M8T]$N*UTB4RCKI=B:[#Z!/>2@?:+]U "V66(Q]M"/"HL0037$4ZB*!:6LM\= M"U' T5-P)+Q43V;.;'1[YIY1[M">72S 7IG@DL()OMI%Q>NCY#[.%-11GGR# M?!P(A@F"XCXO7)[C8=$O%%/"2RTHX34_I3F:=P5U)-G=AW"*(WU.'!E04+T,@)F_,%%:9LXM<<9!#7;Q:-P-T(,71..9LR)Y1P4!"G :\$9 M1#+$O C#O)%\SZ-QFMO(0-O##?O-,V]R9SP5$R <8?P 6 B .'#\83YT'WT( M43SAWLE<5+^:$85W!.>#V^-[!Q!.N@A_4.N_SAS]2(F\8 $']>T32? &@:]. M,."%CY:A"H*)]SG*$(<]&<+1Z]+YK& TT6&AFL&3AH[H1@G+@K) M3%7* D5%Z@YWV H/QGG^=> [W0PMQ**F02\9.B-B(JO++G $H&%$ES%/)*GD M(,HVP:\"EE>#>QIR#H]ZPE18"3Q"D,TMER/9;+!7,XIU9HK0TNGAX0@GUL)% ME^ (./_K^RW2YU4O8\Y"?!>($*_#1#$G-[OD=<75"VBES'_&>PJQAL6S&(Y8 MZD]SKW E3H; J,]-Q;8 $'(03&'SW:\!?V#HQ%_!S,DNM:CXA7O(YEV+7"%^ MCH)GD9(%0V812QX;!=&$ZYI#!EOTQ+,PL(@=GR[O&76%%Y*?*[3 K8$ M<)C&(\R[NK*U8N'NQ(6Z*3.F2^Q7GX3)7MBH#$:>_#"YBC@"SP,0EB#MQ\1^D M8:ZKY ,M0',>7G,HS]DW&Z'JQ6\$PSDXQ7DLSL ?Y9#)>G_#FP :8G(T3.E"I7BL!-Q,;OF;"BI;C]B\>^",\3#(GS-L$TOK() MZG0)NBL#FG/,N<.%)0)P$DQPF.0A>IGQARF2+'\ QT.=3T2[1=SRPA&FM7"3 M?+KI6J?(Y,?D:QB]!,SK,[H"JKSX6.HG&6WCS>F,>C/DFUY/S2) &#(-K%F6 MDV<"NI/C%](+I>6)F).Z2IR?B^4DFU/GG.0M.G6_3$=,ZYJ!6QURFO&44H"K@S&V]SHUP'FI.F M?M@+Q"IF>28H[G-\&TRS% 6+XG?)&6AF+'D:DL!UE,7LVFRY /8LJYXTN(QT%VTEQ<)UQ-$]*I![R-LR8>0)&2KL\? OI,L]V"5'-207'9$G+] M=HE/9?)]BJ!X@Y()SUS%7H "#Q[>=@V^3:D , )99WO 6R:APF-.3!<>Q&.C M)%>/E[&0DZ?/KU+@NV>&828+X3?\@(2] ##U9XQ'4 Q;"!"9+54@(,<\9X3& M%$]!SBH^9A)D(@) L\@XP6'G,\#1= \'?*THS,XQ:D08VH,HP"M(#"=CQI!^LN/AO4!J7, FV!\GDPRSC^9Y&+\K]9C MBY\$DCW_@RMI\92I"2LBU[!1+*.L8J_$'IPV$W$2?BP(2<3]+.OHOI D0 KC#Z7 (!1 Y MF;?4Q6@1@2T$L3!IDK6G I0 MGSN"\37A?IP^T0.20FMEJK@\"F,M'_PF7^Y5!(8*7YSP3<:\ZNM\@"DH("X/ MYAIS8T[0>11N<'H!9_ %22SXO9(1<\#$#)$N\K@NPO/\\T.>X,S/VX^>[QYN'NY@%4A(7#[_=X_^GV^O()_GA\@G\^W]P]/9+[C^3^ MRXW8Q?%7O?KZ]&-F_Z4#S 7@(AR>$16ND[45R_F#KSY6*K*G,^" H&T"]WNW M4Y7_E%L 4P80 P,_Y[Z04<(N\E\^@,#$.ML7?LAGYB]]6(SE0P)[1OL5C+=L M$CZ?^'I&>RU%T%\*1)=Z^_V=:;0LPUK[-19[?=MWIKY^TDUO M;EJLW3(MK4*C-@D"Q7#@/<_\LN/H-#8KG)=#HE[0106A '8U:\?*/NBIJ< Y=73(.,J242IRH-= PW&_]GG; MFO-LU:[+6*_W81<<.N08A8ZKTA/48I&[3[!%>FT%1ZE:X'8#CQ-8UJ"DD#I ZZ=E,.VTQ?FM\..Y8X4T^< MT=L=VK;T4G%&\JI3PSN#ZJI&3<66O$KB3&&<456%6NT2>54=O(<%H7G%8YEF M]_3[L-FUE9!823G50R_-5 '!U(W(M6]Y5V^ Z2KM=#9S\,,I",U&1LO0J6)K M$AF+ JQM=ZC6[AP<8-)]5<$):K'(TMQ7',\UL^+ZR&(?SX-@@;8;Z&K"^52J MJ6W::9O5,.&;"F15;U.K8U0#R)(:UAV43LVV30W5JL9!-17(AJI1PRZ1Y>RN MAQTF5J'VCS;(I7&_G,U6Y%*LFJ=2REGO1+"JUJJ\3OGHY&E?>0S0?R"JU%0MLKLT.O0K= M]=1')D:]]"4K'9$W'))W/XI&VULH6KK;Y^FSTZ8=;7.DD;S[>:,>H+>I:6]6 MM20RS@',Q)M;Y? WMZ=F/OW!^]Z+HN&.-_3#K$O;LS2@WL Q-97J97K,3@#$ M> ^BEAO^*BEAN_?85JC2E@[Z@X)8!2NU1&]-0XVGRV$$B_G/M&O87 G!:>%* M/TRQ:%DWV(_[N=::&3)D:_.=J=1D%Y0$:LF(NL-$#YO4-H]KL-8;7CI5]'K9 M5)47'T]1.JO_N]LUY4&5R+6A:774?6S0?6SCC=% BH6*WALM;TESA[NJ[-@:U:PW&H*'/1@9P24CN%YYG'E]\I!7 MIT7[>E9X^N1-Z5]^[&BJ]D$:,(69'X^*E\:T1,8* .Q8R'A*Z6DU&+WZ*]QQ M])-RU\S%DSLQ=G8IW5%31\ZG&=369+#D(5VUJDH[6D5BLR4EK#TFL,5-8[-+ M75+"]Y5-T"VJV"4F:4JGAG1JO%(C>/<8/W2Q4?P9]OIY1TG(9-3UF4D52WE5 MD5S:CRMD1X:](%V&W?!R521UOI4?>E)#+JBI-NV8TJ-QT& ] +$A/1I5/Z9.F]IVN35\ M&P[BCFI2O4RG48,,\=O=Y%[#S1[#H(K9D79/$5BIBD[5MG$L8)T,#JI*&RQ* M4R)A(6!9;6H=EF*EY5W!"6JQ2&EYKVRNR-*#Q@Y\M\);.8@UN8&%:IG4*KD$ M@,28.F&,;K9IN^2&7I)/G1S6=110-,LM=2TQIDX8T]8[U.R4WYBI]+B;.348 M)B=>-.X&[$V*]KX&JLGB&^1F_-U)?'>J]I,1 [0<./'W=-@JZK6H'"S6,;T: M\3:E91XEB4B><8F666M+PXCC>W@E.I2)#MI1T$&><8E1'"U%=HO[/D?O=RJ) MY81!];F])E0L1,2C=,D=4+7?O!&-4* MZ;YKB)TGW7?-/V.UM:7JOW3?G18Z:)N#;"3)U_Z,M98B$U&;XK:2<#@=]UVN M8$L'WF$<>!UJJ>6&;C4FZL?X^3U.]-,CC]]FL7W\O66_BUPX'76@:OQI-'HI01 M]963B&0;N3:5%N,HP\%I!>%)-TP."_F#'>*S*$ MK^'+,!TDA(4>R/A'-DK9L,MBHBN4:(JF\@=??:R 6A##( F,&@312[*P^V)' MQ=%A*1(18!4XHX1=Y+]\\/QD%#B3"S_D.^8O?1@Z<=\/SP6276!YTB7TXQ.* MKS^\^%XZ0$IH*9P:*\]+-@H3?(0D\9)G^E(L ME$*F&#X*>?-5.W:)F9[,0/-S=90WA95A453=? M A\_-K09H%4-!6![W+C;V@/,.D*=@5-P*3R.NXD;^Z/4CT+9PV!W^-DJM2S9 MBNZ0$-:IL25$N0[F:L-/2;.5K8VU)"%\'X@M[.51=I18,PRB+W'48TD"0L\) M"(SQ[+NRE<%OI@G2S#A\-9?& ,Q DMQ2B%B:16_4\K$0)M4D.NX",L/4J+XE M6%N:1L6@^=D)G3Y>MA87#U(K7/*R:3I5=5D&YY @QI[U96J%DA(*6;%ME6J= MAR/1E&<\N22H>.'*0N=T)771III4>4X11&: C"; MVM9Q=?A304:K@SXW>8E9O >H8M'V$9!=(\VIV MJ:E7Y&:CF0 VJ&54Q/J45+"^#3SMM.7-T4&#Q*E=9A/XJM0'W5O:RI[&J<72 M=[-J.7YH9LLR*ZZ_/$6I$TS+,7Q_3=(,L%G)@PV%JAH07;S35BO.&JG1ML!" MW>(VVF7'>XA0E[A43US2VQW:MK;42CH2+DD6=B)H9U!=U:BI;$D"E"Q,XE(! M7%)5A5KM"K"PU37)OJOP6)5>R\!N:$)5'D6)CS'8%S$+G-1_9K.R6%BX:.[% M#.K*[!6G"VK\.'W]RMIUS/\WEP^W M-X^OCJN;A[_^O3T2)[NR=W]W?G\9T=? M^.H:=Q_W6<.N(GLZ&X?.V/-3YKU;LZ+5E%X.ZEQ>_^^_'I]NKLG]EQM$\KL_ MR,W__7)S][@6N0NS-U%R!GTVLC)@K>KBR**'JR\E:CZRC9MDKM MDJ.@),;4"F,,E7;TBG1\D7SJ1+!.IXK5IIUMD1B24TF7#:U$1*7[M]C7T3S MG/, (&SG.XQ@@?_APD+FUKT!3=&86(NE,J/H.Z&K4:MCEPY=B?]K3\C@!?=+ M/Z&F0E>GBJZ6 MV=A6./_Z^VPO$^[CMA)@AYRE:2QF,W'<=XW8&1@U$Z8/$. M]M16"+V)5:R Z4#MW]XG\=#T)3;6KJ M:T]"6GF+5EX'@+56PDDK;W>87MW_\_;Z7+5);N)]C\@Z>>U6FG:'HGRJM*5E M5^$#TJFJZ*4?4$.!:U!-W4$5;N!-XMH(N[W4&3EV?90#+KH.Z2)%'= >YJZ" M2C(+)+R9!A*&47A>-)A0EAAXVU:KS14[MDD-62-%8M+W8Y+9H)K)@@*]F4'M+#UN9!BPQ9K8W WN@:A5I(2/YU*E@G:U1TU E MGY(84[3?FVY1Q2ZQ5_,^K)BBL>)RC.J,<6HI0WLHNB"3A!9!*JHT[,BZ9*+0 M+@60>&V':D!8TL':)D^B5$0UCJFA(!8%)LH#\:DE)LGR$_O'85Y]HAH>B89" MF%>@J :$)1VL=9+P*A35.*6&0IA7HBC=IW RMJ4L1W'H^Q]>C4(JV >T-'E% MBFI 6-+!6CH0Y2JJ<4S-!'%6Y$):FL<"N"R!L4?-6IJ7AV0-6 6C&@"6-+"^ M9X"J5*1/13,!S*MA5-:VK*L4_,/Q0Q*%)'$"1J(>Z8X3>"9)6'+RU>!_^;$# M&/=A(\K)0FWS:5(:NIK7%VPZ?JY\,^ J$;&"B'A*61@U&+WZ*]QO1:=&9%ZL M*O4T3<'8I=23#&]N=+"JKJE4+_F"56),G3!&LSK4,BKBE9)\ZD2PSE8!Z_1R MDW\DQM0)8RS;HE:9"885K/2ZH435,0>JR>+K4'=GYT3LS[S25?$T[&;[?U2S MI6_V?'\G)RAC4S^O/=9:GY6NM)3-ADJCSNID2%!M&9($:W)65LO>K%'5_JR: M[7S^3AVJO!GJL]U6U[6CAVHOBAVJVW5E=J/G[L7OM_R6XQM):% M<9*C2"1^7_"(?/^9S8K88YGQN1N[T4A9?.,&+,TD6IQ_ZX?G2VG>?EP(YL@G&@+ -D$039!6&B"0 G[YC*05F KDP1+7!'/21W9&T'V1I"] M$60Q_$/N6/9&D.@@>R,8J M,:9H5)39INUM3;ME.+[$NCU7,5:H57)I$HDQ=<*8MMZA9D>&X]?_T3IX8@LB MY9<8[SZ^$8<'* W!"D](+XK)-& )E?0\;_:7'\W.*\RMS:F5@@N-JVQVD)83 MIUW=Z4TM)V1YIT.WG*B>A=#P4WI;RPE)" =O.2$KG6V-[_[^SA(-SW':WB=" M5IF:A]?VK@^RXMG!6C5(5)R'U_;&"T>0#(TSI([07^&TU0VN2A^RM( ML^K8=/"F_@J2$ [>7T&:5=O@NMT$9! M4L&!VRC(+D-O!O=M^,S$I2WI.WY8I*N"5(YW+W\OE>/O*YAOV-30C'7U\J6% M6/H)22(X/!%8)NWHY1!!0XU#V5WHNPA:WG',DZ?L+B01L0H D]V%Y!B'&N,4 M<@HOL:[._B.:ZWG@31JCH4KL;>A&0T8086'KS$U1DQV]#LH_>97V3+6IKJO' M4M!J#2NC375ER$6L-*U:FI'+2P_4EZ_==FX(Q8#(/C M;0 *#S]E0WDC\)9+0JU=;I>MA@-8I:8J^R954L).CAYHE78HU MU)3ZIQ.,A2!T@B!Z<4*7X?6 QWHLCD%6ZNCF86]X1[%:$KP:C5W^%.XY^$G<1JVX<#MSPZ;LUYWI+C"F,,9I*[0;DW$FLJQ/66;I.K2VMAR6?DA@S9]3I%FUO*?AQ$L4. M]]=R=5\#U63Q#2JR>.UC]S"/B(>P-!"LSNDST=PF(=$X35(GQ/V?D#@"SJ;JEOIQT3\HQ9 CS=FUAVAIE MU@9/-DF1UA7N36F9TAB7Z%(XXJJE5J2\M.10)X-RFNSA)-&EL-7?4DH,":V^ MKW _OK:C>PD/N>P&^0>G@0*YZC\-%O@"JO^C4/UW"1O8)D,%J,6>-SED&\ < M=]IJM9FDTNIL4>-VV>P>9*M$HWJBT;:JR$="(\FX3@3CM)91#8R3:%1O-%(J M(/^XWOD^=6!<^-?SGW_[E?\0*^KBE]GB%K\['+1>M:_7$%H?'VYNR-7EXY_D MXZ?[?ZU9U.H%YTN= XS+PI3%: _AQI< #EL*G%'"+O)?/GA^,@J^"E,YA;) M-;P-23J(QC"HEWR/_3A]M%T$,()GE"1"7C'%+(\+QF_K.?^C"7C!R2 M%ZVBF:-!.UJ)G:HDQM0,8_2.2FVCW' SR:=.#>M4JID&U65NM,29PGNS-8,J M1HEA9W7P(196*D?H7B2C<>P.'-E3 ]L86=34-5GYM0BL+)5:IB6[:>R[9J#1 MIAU5ESA8"%AZARKF08%U&NX%+@G@#0!=U$M?,!K18\\LB$:\]: ;)85**LH2 MJZ];@IGK.[W(^JK?"5TLE+=6!-7!8FWZ"6F&1MM6^4?45/"".62I2@U*#%=: M_GW$6 'N8_\81"^'B,/??LM7<]]"X6U6FZ)T%:P:;8M':H>+V_U$L4KLJ0?V M:#K8;M86[]01L$>RJ88CFM4VJ*U(-B6QYVV]PU2J=0JE:QP.>YH=(O2=I?3* MFZ$>J]Q_K<&&^/$6PX3\\)DE,DQ(7J6N#MHTJ29K#$F,V:5Q.5C'5OGN;,FC M3@7C+ 4O4,IQ<$ILJ1NVF':;=C2S3'?X#O;,L2OU[*I\RV+D=;W/6+8#>G[H MA.Y;[0!9L.-M6ZTXLS14B[;7MSF7]3HD%A6Z@::VV2D;B237.A5\:]LZ538$ ME$BN);%H.Q;I!IB56KE8M'N1H7QY<_-@44F_-SE^WC>O/W3S;10XH6C('?7( M718V0SX*?=,)R&?F).-X+K6@\%XJ!X)7J,1!\"]&8C:*XI1$XSA7M&'CL.=Q MD";$#T'G=@&?>*_R%S\=\+_'(7?+CV(?'A\%L)X^"UGL!,$$OVF& =)2\,)*,1S P M#]_%I?&#R5?%U^$"=CHP1Q[M-+?Z879L,-# =PFCL!_ACF>9R_E:^..!,%:BF/1CYN!@ M:0RG,G)B%KJ3'!(Q>_;AV/"-V5Q\U)Z8Y)F#<+81FL\7A; KOB@W"J.A[V+' M!9ANB,?2(D\#EK!-@" 8$1U&*7X .5[!JTC3'Q8AC@J/XD"/A,E#CP/\.\" M8J9C !,!"N)\4C@Y. 7>'_A/'!E,X@F@V@<>#B#PR.QTX&3SA8W7=+ ><9S M&, "8$F!/_13/K\8;C8( -0#^ <1 M;0:!!-$.L2@!;&5X(-XJI,:EO8+C=*E#!] Z2#C4/+_7$TOFMFD"ZPZ<>"/P MQPE,VIV0") @AH4.0==#$Q;WB4/CP?#S@"]BCIX X&Q@V#:<0@ #N,Y(@ >Q M96DD;\S?&44I+ SG!KK$TTW@;Q:WZ,BL,O/++S[R^VMQ7"WV'$1Y%"@T#?B9C M(.L%[,Z!#"3A]/F) R('0+>S \[QE2*LX+%@\A\V0Z#N. 'VF,"W0^ Y4/@",4\9HYLER#$\+@](&4$5,A=V MX,03A('@+H+#Y=MO+<_H9PB\5IAE L706A96S(,=^;B[BY@A?CVS6:$\+&4V M]V*FH"BS5YPNT# <^ZM7U@K5^9^#>&8]]=EY%SC'UW.G!P=UX00OSB19G'[H MA^=+:]]QVBI*]#>0 ![_M)7/WV/813KAN)L+)!>104CX7%E"+)U13&%$WY .89":RY MX#H//C573OZU4,DW6L;YDG-R)<0F%WW\1&<:'\M62)Q\]8#R_$S)F?].]+\Z M!\Z/LGH>^;/W*#P%CSGNWV-?L+MSSB&QV>80-'#_/YGZ!8_!7I^K-LE'SQ[9&^TU#O,RUE=A MS)MJ2%7$O(U8ER$F/-%'G006E3B!T"QS\;%'L= TU!3Z5Z.1B_+!RCT9#9(@[8][[+U65N5GJ T/:'S%!&)04-M@2K M!7K"(H6GL'@@*!@27Q;P9=Z(JA"N<"86PMIJS;Z0=0G?!E=KD8LE^*F_R-$6 M&1I_ )Y 9$93?(B&VC?">CWFIKGZ[ 4N*X,"T6O1,J&V8N;@ )4 >%2\$1 MLY>$\/_VC@B?%3['?5+\N%41&!'02-_:[2&D I9?F&OBK(+:)5!ZWR/22B0>O^CB] M9,N!PP35 DA%4 [ZPT#92">+:^?W$FGD?IT2#L$+1$"(9\2Y$SA@@V\&W$4%IC#.S^)GWV5%V(Q,L&YR MRJRF4\60#1@DPA2O&D)-H M6G)37$D'6T^I;5--+=?2:SB$#87:]6F@*6"JM32SXM+P*<)XT&T1:4>HMG9: MM?CW 8=JTZMITG9[B\-U;[ X0D4DB9_-PD\=+-!MKK8JX*=DM1*5MSH'+&K: MA?JB2%XK$;0$!.7=Z8R*(^CJPG;Y^DXIB>=R2\9MU9)XLI)7646U+%]FNEI> M]0I@'PU9+-)\,<-DX(\P@Q)WRO-CF3L(80O]B4BJ36/'8R1TAIC'FSIAWT=< M%!FT, @6$1/)+3!WR.;JDO$LH!G\DGQ%?S(G@*\?1033K.H4CO&1=>,QEF;2 M%-6DY!*F^B<31?CNW33JPKKA&YOF->=XC3;V]QA#HN;G6L@RVI8V7?DL(UQ" MMJ(])!1-\_EX,37"*P]>+F')*I#-3C]I\9?VG8HDJVC5E4W>[U1PH$)IP]-" M<0,G[G.R=L=QO)Z?S1>C](=8KTZ4^O)#P#N.I$"O-W-,8GF0E-=79#T@_%14 M5/@Y2K%HY R5,W0,^(5:2Y*RTQS#!F0U'031A M##[':GQ\'"=YREXZX,LFSP3ENIY[5)]%!HL-K MCK)DOLLDSU(GJ,4B99*G3/*4V3#%]_;+CQU-U3[(_"F),37"&,FG3@WK+).J M=KDAVA)AZH0PMJ[7)9"YTC@B;\S9L*BNV!(7 MJX:+I^!6D&F>^Y0I*M6US80LT]N^+QU!I99=D41:20=K%7>+*EL*:$@Z^,Y0 M<>9RI1E#0OA"7_(DTAX MN@X^D[ @:)%55S^S/2WN(%G: L_O'/CQ=#/)=#?P[T^&V5+;[2DT\.F?U):M M=?*/*!I.(\QO@JDGM#@(BC5:Q/%F^\8^N@@LL-J0+CAP:MV*L7CP_Y;TNW6M M>^N0:)<.G!13P%P'O@R8$P<387]W_YWC%7'2-/:[XUE.%R:IS;H(1V$_0C2[ MBF(PYI_]>)P0ST\8[TX(8[&A[Y(SGK*:0XK_\:Y%GG@ZWMRB> [;7)9OMLH< ML#@_SX=.!KS+*!#QR\!W![@#S._S8H >)H"-'.2T_FC6-G$ZZ+0SHB=2 F$2 MT009^ !"(,Q=$ !^0 Y1?2I+&,0)>X[K!]B9$?1B3FD 0$R#&SC/F$G'>*VJ M*,E6"_#A$%E(TEN',-5,QUN[VEHEWLU>DYEW])+\6SH6RUQ,#U.C@'9;+=VX%R9K[RBFX(%#[9Q"9+=E$\ M"'-KRQ:*5<+!4W =R+RZ?6JS>D5:TC<3O*998L,X20'%[#E3K<@A-17 6IDN MO;>DT^D5%X$BEVY;^*%,Y9"1\D7=J&;5>R-)Y#Q9Y%2ITM[B0:L">DHV*S%Y MV]TF594MJE 5,%FBYVFBI[&]A7SIZ%G3;+D#9!_=AL\L27G65M_QPZ0J64>C MV!\Z,86^-/-Y70:8I/C+T$ M7#;/I7@ \UL>4R?TG-A+8$T>9LF(7)ZG:.2[1-=4 M2@X,JIV.>/X@D_,; 89'YHYC@ TK]51Y[A)/;\H2F+RLCYHXU:U)2^(Q+]IW M:E*>32F2GQ+\?2+0).^+F35OS-89LX,T;[SGI6I@Y&C(R%D0)]0?F'@*\>,8M0#0_S'+Q>BE'LC"/RI,IUV,FG>-^F.D[=D4'3_('0ZP6 M*9:/(QB$XJ?_>QQ@RU5-$9&0B\,#6@U9[/J\3-(S"\> ?A,7X3A.$WC 18)9 M0QV7XS[@"!]:$O%&(EZ/H9*,YU0-SN,PH9WU>DRD .*S'1%XU0D24$\!4_G9+-?7%3'Z]I:O33/Z%3LX;BAS@FST_ M!II>_$99+@4 ].RQQ(W]+J?JZ.67'TW[0U9Q8'XG/YFP$%.=+@23NIUO;($1 M9FM:*%603TPR'ME?2T#3A7C$Z4;/C&+B, >\R)%>@4 Q1#=_0(;1UR^H"V $/6!_Y5-C/,2=K8ZOK(,"U%6 M( 9=P49 -OXCF:=6[/'K)X)"IC4 D.DGZT#@Q+$3]EEF.PA9@5-@_0H0?2A] M<. N"UG/3U<+?/8-)6["$3E)(_L+_U,X$L]:([]_O.U M]%\G_,ODOHO,UUFEM,ST#H?KU^G4^EBUF9_+JY2 ML&F[,$R&6-D%&.8P@ED"_RO6GDD'3LA)A]=9X0QQY^&/=5E6I CMAA46 M#Q!*5DVJ<*T5+X(%'M3J639UZDK410C^I.75T;.8.1^XNGFXNWD@5_?SK]\?;Z]O+A]N;QS5'>?25WM]=W]P]WES#8N\>[S_=7E\^ MP1^_7WZZO+NZ(8]_WMP\'7^MJ[GK):>U1S8"RNN"/:2##3:UT:Z9FWVJ\D^5 MBBSZ;!PZH X#SWA7A.A%2O[1:R;9=LM2K+>43++:0)KV 8KPM!7](&6(WC;J MMK6:!RX8E F#AM8,JDUMBB+5.-Y0Y*8V^Z]T;8X*5I2H8\F*H[*:@@$2E]SH M.&B:29ECO"%4VJIX3,\5UA&%:86YN%AK)A&\:29XE@S MJ=XY;J_V4Y'&FDX5S9+">)\P_1*SD>//]Y?)N]>>F%@V5(U:#2C#V?1C4E L ME^BDV?V:9M_5]BL]SALT%EVI2]MO=\$-WU#]A1J&0E5S 7^),9@S%9E\>(/%R]">ICO&4BW:UNM_ M[]/X@^HH!E4Z]2C"5B]V\("_GT>]\W'"&JW==&S:WE+'7*HV;Z1/H$YS2QW6 MJKAGZD6=*WMT\Q;7IRFP%:6#1HH4V-4_*)OJ95YT-59@_Q%%'B:--5-*JU35 MVK1C'/[B_10%M:V"H-[2_$<*ZK==;:9.V/7E,ZE M'Y.NV523LOD D/T4A?T3B3TT.J");RFZ+<7T&YMNJ K5I)@^ &1%Q&],&LB\= ^6#5Q5$0B(8? MSC=>SA[=*+"AAL8BZ(9!.Y:,[3\(;!6;=M3#QWFH MNB4C5HKK\H])LZG5+K% AHQ).-V8A+=QR1I2F4I-4Z6ZMMFI)O68[RGIUM9. M[M*\TF.<7@3JI^]WV=97D5!I6U6III1X;R UOF('I>N8RR.31 [HHO7GVMDU M4Z71.[;,Y3P4;#'93C^\LGAZ(EIX9T[7*Z.:"NUT9#W,RA^312V[? DMO3(G MZ)5IO#=&IY:B4\T\?+G&DU1>0'7I4%,[_)U=Q;PQ%6Q]>/ )3D^#7)6Z4#3J MO9&.O%K>TEY%PV$4PJR1^[6Q0JXCKQL.!%E]"KF&9&'$AA?1>O4,Q)WY^9P/!M:JF==U(H M5_:0#*JVC=(.J8D"^=)UQ\-QX*0L:R '.QN.8C9@8>(_,Q)$2>%ZJ'7$*%6S M:=MNK\,G*:+?#%<%.W\<$J[2/5SZ!/O4CX2;N-+,4MR?)0L>8K:YN$TS!;%. M.[I-;46Z,2I^4 8U.AHURRSL+4,-9*A!7A>L".MM5IOA%"MZN=..]RPABDZ]KLB1Q,N:XF6!PIM'P4O.\=^G6+X-_O7\Y]]^ MA1_Y$N;&;B[>2!7]P]?[A\NGV[O[\CEW35Y_.OW MQ]OKV\N'VYO'5\=5TDKO[ZYO[AYOKF&Q=X_WGVZO+Y_@C\TAA&?($%X<)(2%'O/((QNE M;-AE,>A$E&B*IHKRH\L?*Q79T]DX=,:>GS)OZACA?&")_\!R F>4L(O\EP^> MGXP"9W+AAWQ0_M*'H1/W@7XR$D;:6>([G)>(KV=DU5($:64Z9S9S]G6+?[7$ M%<5WIMDRK,[:KY66NO:[3YVQ M\N&5+"M))7C%%H6)PAG+9\%/;I"?[*.P;5VA<8?,=2TP=K-22XOQ[.1;Y0-> M8("1[Q9Q5]^&(&>B,0SJ):]\UF^U\^MQ\"@U3V['RCY(O:G .75TD!=+>YZ@ M%HLL[?9KFV]HZ'M>P/9-'* ?%HNDG]J%Y./#_6=R_^4&K=V[/\CEU=/M/V^? MP,YM=GY$5<9XNPY6/:RZ8^G:$-"B40_'\Z,6W565&Q05W8-JF=2RCY)9(@^Z MS#WH/$+Y\#6U=E.N)4Z4BA,=A5K'Z0PL#[K,/;0QA;MS^.H^QPZ@+U>KN?30 MVR5:?*01B9D;A:X?,(R?G:H[^ W^[3K)@(SBZ-G'FXSNA$0C%CLI/$(<-_6? M=^JW54^-MBIC'"BPNUQDO&8C0$#?P4M=?BOF#"-8WG_X!S6+YBZLO'94JAG' MS;JJ.<1 W5>,JFF!#0&NJ9NTHQX7N#6'F-JA]I:J\E(OV16JO*;)>==)F,?3 M>UB8"+' ON'OC>DT5!C+3*I9%2F2UU 0ZQ:UM5T;O,GT@*.+?].B:KLB-9V; M"F-5H>;.S0ZKG[=:KDS[@I9S@D*L%\7$:T!AYN*.V\VX)#7*>6AU:-LZ+KQ. MQKS1J=DY?*&LYL!+PS8QS6O'5JX<^,/Q0X*E_IR 85_E[CB!9Y*D.:6_BT+B M;=UZI2ZW"XS/-+5-.VU;%HFI[AE).F@X'332GKD-GYFX.R1]$&E--5Z*$*?4 M&A>+7MG4T Y:2>)B3MCHF72CGZ,FDXG8KM<@IF2$G\XET#PPE_G/6)RB<-'81G$8 MBW:J4A.QH1 ^TQ6J2?]KM8](I[91?AWUIH+7ZM"V;4K/ZSX]KV$:Q46*^-82 M84RJ:6O)4;JX%J[H@;1DV] #71E1O:U(-"P6M*1MZ3PEG:V[!PPR[#V7Q[P+ M>Y6WO#@U*^5,U:BBE*-!G )X-5TO';;2/MDDB!1;+?V$F@I=O4W;[;67A-(\ MV?F2T'4!7&E"1LX$/6M-M5(TP!MM+5E*_7 16#;P,$O&A.S;_+.HL:57BD3$ M!41L8YNO@SH73LM* 6X?CW?/8VJ4"J%24Y4IB8>$,(A:HR)Q-])064\'.E7+ MS!L] 1#K.GI"ZA(14A,9=ITGX\;LF87CIEHLJDHM3=8:VH'8#*JT9:FA0R&C M8AZ^GE]S ':F:U2Q#NIO."W+Y9YW#W=B-!:].=76M,)&7&Q4X(LW0:-LJ_XP:"U_-H):Z-F-4 MQF7MG &9FRM8E<>?UAMMKO72H99RM,*9=0>6BF5&CY9_M,GYIEHP*VR83A0T*X]!KRTJXIF-YG=*AJR0O*@\'7I-9Z552: M,V_QT^WJHN-I63;7?C**9I9-UE-G MP */]**8M[<^-6O&IOJ63"ZIQ4EKYA3.25)"XRE!)M)7;>F-3Z0_&R?,>X<= M_$0PR$FDU&N*2353EFW;Y1(#*]VM=Z5)T_/-M[D*)E'(T,""H8%VFW:TM6U+ M9!)]!2>HQ2)E$GVA)/J/MW>7=U\%O3Y%8?\\9?&0>*R;$C])QD[H M-K58L'0SUP%B)Z-ZFHI"E2VUY24Z+B0-' EBIW7K\MU4SC1S4_4_J0M^)W@[U%#*">.7%E'! C(:54V9R'*X,F.T MK97#7QII#3W%S$G&\20S?AI?(UFW3'0,RR .>:E3-BJJ5-4D,NX@64WET- Z M+;/GVL?@TM!+R,CQ3R[[_JS=II:]MN"DU-2^-P#0I*HE;94J'Q%ZDQ13DL#! M)#RP&*VDFM.-M%9XU^*FFB8VM=:7Z)>ZX-*=:-LX:*&F$S5).M0PCE95NN; M:M..8WR/R&Y9Q(3(/$*[F>'SJANW,69+,T3$.U:-N6UPT'O&ZP MS;6*AC1B*W!$;5NGBFSL<\#2?"8UM5*-V!TTH%K4*JCQTIM49N&FUV,NSV5@ MW]R!$_89B9V4$?%[0J(PJT\;>N(7]O?8?W:")G=ALJEF'#1INSFPTJBRI16# M=$2\V1&ATHYV- =/S8%E4+UST-+YTA$A'1'2$3'GB/!#%^.F&#GSF/B-%V;Z M'FVA448#]M!1];;,"SL@C%7#WEH:2SHHRC^G,]5L4\5:JU1+.MA#2'"G'!=H MDZSAJW7"BS@IZ;*^'X;H; =K>00S1$7BQ>J(3IK1IH9BR)RTXA!KV[1CF](2 M/@1PVZI)X3^)CL43=@V5=@S]6"F2TBBNA5%.-+>]V@L1WB$&)EB>'EJI- M57.SRE\Z6NY#DDK4/CG4EAQ7HF4%T;+R')?K[N]3!\:%?SW_^;=?X<>2L6=H M+0LWG+<"NXA9X*3^,_OPXGOI(-OL_(O9HI79*TX7S(AQ^OH5<32__=K%A600 MXA\O_.Q&W@3^&:3#X+?_!U!+ P04 " !"/%U32E;(^7$6 BFP $0 M &-EG#O^>C M")WQ) WC\<>27)9*Z-]['_X'X__^V?J,:K$_'?%QA@X23C/.T"S,^JC->#I$ M01*/4#M.AN$9Q3A_YR">+)*PU\\0D8A\[6%2-7S?U(+ Q)YO>EC5*<66Q ), MC4 .J"HQF2J[O:JG*;X6^"JV=")CU60JIAJ1L*HI :<\"/R [+(J465*H")X MR5(53_(D3=6)I^@6,0A5+=%L/P/N@,-Q6F4\_%CJ9]FD6JG,O20JI]PO]^*S M"CRH"')+1<'S0K/9K#Q3RG'2J\B6957FHK)5H6HXOU(NKU"4))*L5,)Q%(ZY MZ,!UH/.JWR)QQY-^25B;R_] M/4IAZ"6"99)74HWHN/>QQ,?XY+@$ \PIV_LPXAE%HEK,_YZ&9Q]+!_$X ['% M[F(";?O%IX^EC,^S2CZ,E;U__.,?'[(PB_B>SY,Q%A(@2\3Z4"F^_% IJO9B MMMC[P,(SE&:+B'\LL3"=1'11'<=C#@2$\ZHHR)/BSY Q/L[_A.<.S)TD](OV MYUF+!Q]+H6')&M$5U9(5I@:>9S*/@@BKAJH0KBCL6VU-RCE-)32F(]$T#ZOU M,="W. !V$AHUQHS/_^*+$@H95,V4TX57B\\^D]991[&G;% _ZQY9@^:@(=GM M^J*S[(?P>]ETORX[@S]#NW8B.8-/H;WL:/; 7W3[[:]G[.@P](Y.].;1X< A#:D[.%ET MW1YQ:KU%MS:$GP[IMC\-G'9#;;JMD3-HK-XYA;:T<=>-U4[;5CH#>.9^BIJU MC@1M#YONIZ$SZ$:=D2UW!CW-.>H0.P(:W7IF'TOSS^[^-\J92GT0*^JI@$-< M!QSR_0 KDLP"C6FF[\NE/0G^F9)J:,J'RI7Q?,KAW0>T90)Q#R/:>QO6^X95 MN3RLB@Y*@QHJUDT>8-5@!%N,4&Q0/P!587!%-TI[ 8U2?F-$*U8\CZ4\C$YR#D"JDH/&7U>G MQ/67]]9?7:U] OT;L_4G4!Y)5@-+8D\0A64)"\2]_NR<3'9'T?63]>=U(Y4K M';7NU?-NK%P"ZPI >H'K>7?>9TQ\DTN7WUGI@E$XQGTN#)ZJ2LJ&-LG>ST*6 M]:NR)/U?*2^Z]R&=4! J+ZE !<7?13TW:A,T8QJ%O7'5AT[D2:EX>?WH%8_H^%^[*>A0, N2,"@*IN&25V43 M",P_S@JB#:A'Z-TU$S(19)\X#;=>0\?NOEL_ODKS*Z3VN'YPTFJXC?HQVG=J MJ/[?@__L.T=U=-"T[<;Q<:/IO" +9",6VC3MA^->%H]W4:U\4 ;K65.M%R1; MND:V>BO9WS;^]\<_95UZ?R=#(YKT8"9E\:0JIM!KD:S#9LM&3ZCKU\Y58:2^ MI*J?KU5]QVV%3;5Z!??8EX@+HF_NNZMD:_T-389%(HSS(IU(TF M!8!MJ^ZXJ%7_TFRY#QZ(VQ3ALXZ?O!&77Z9).J7C#&4Q.N:^<$0+#),5%"=( MUG;8.Q0'R.US\7R:A%D(K=?G?A],18[V_4P\EBU%_56[2!A@@L<6G\1)AG;6 MGSD%$XRG&>)G(G"4Y(\Y>U=]?"@M@@3P]CRK,F@>CZ#*O@!8S.@"+X 4S,>W M0>Z7W&"L%V;D[X6]4$?C&Y$U*FN>APWN4ZPRR\>>+FN84$\FLJ4KNJ>5]II^ M%GO@%A!K-P_HW?2:"AE]"81]928%V0P]GSPPU.*],!41M,R!)[^79 NK0OYF M$,(#1E6L:A;!JJY)V/,T ZN&P21%D0*)**#&P"D'R3Z($X"G/-#XFHV,VX5I MISZGH&?$0!= O!YZ1%-T/.&^\,L9"L>HD:7HH _N-4_>K=G*J!?Q-G(!7 MC('RB$Y27EW_\7X=[2SBLSA_Z?UJ+QRB&V MK+(J:V(&9.!\9VS=\,I=+N>3HY*QF\\4N:Q;ZIV/I;)\Y[/O52OK95G2'K]: MK6QIYJ-7"YU@JLI&U5;R#BXZ&891#/;'DE):OS"AC(&O6263.9)O0\8;8QE/ MGM_"D)X$+"_9"V+)1$2<,CY)XC.!HE<-A0)-&V/_ B".1>F#>#K.DL5!S+83 M7(OH;&=Y"NW9N+[J$Y^^SN7P3=/6(J$E@; MEFQ96.7,P*9B4NS)FF8&DN<'.@.KDD=T1I-; K0K,%Z)_[EDZV^2?8L90THLU!(WJQ#,\CKEIR%@-? 6D5%.Q+E$->EJ2="\H[4E8UA13 MWUA(W^#W-B%UZ;RQ6C[PQH)L$ID MXALJX9IBE/94!YF=FO'N]$Z1O71 M)(H7/,G9O0HOR(G+[VZ*>R5W:C;T\Y[7:P*^RE(!Q@]UFTC9LC9S&![DAY0! MX)_":2+&$[AXX#G*UI;TP=.,EUY6-/WQ:=7+FG+WJS\\7D99->Y^?(N3NRZP MA@&85*7[L$P22':IC?.B(L'LE>'>O7&@YS'4]AE+>)JN?GT& N2M-M+^'#:/ MZHKM#N%'I":!8=:NSYSE(1A@^[,.J XD*F!5=D/L$D"AL&_"&3"X)%D MEO:(*4D@$/Y0I-OR(?I"D^&,+G["S;A3V!]0%&R?))X5?[]-D>]/D2]QFM&H M&TZV/D#T7'/$OP@0,4(42@BXWI:/553=L)']GV>^_Y9B?P!_-A,WGHW?9/X^F9]?U@NJ9IFJ9TI8%_G'*C=4;&D* MQ:8)BD%3&5-,K[3GQ$G61W^!(- 4B;[>?=SP:,2#7UQN'QSY7PEV'D%H)E^@ M9)CO>GB3[GNE^R(TQ2S9T$U%Q[(>@-4C21ZV+-_ LL<#>,)UB_FE/3M,189N M^ )FSH;AKFUV&>X(E:SD6ZP;?TE M,,)C5!]SOUI%IYQU R"T.?I0V)$CV1J M;F=W@L6'A,GWL^&EE\BDV8)$AR>T8X0ZW4\XW5J#_:?29<@WYE,J!X9(DI$! MHSVQ(JM+#%L&9YJBJ%3VE=*>*=]8['KWE*G1GV.8V5_Z\7B;5S%_:F24;V*) MD>G,PH:I*V ;^B8V"9<0G8MA7BQ2[8H$FF@I5@,0LO0:RW\GZLYXE9WHS_'+B#.U/)A&H M*U %]U&_6B!XGJ3O#8?J$.QGGJQ2S1*T^K@R(G91&(CTLG&/,W0L[&3TF:;9 M*C/X[M&ZQ-U@FF9AL'@A]@[ZW!^BK,\1G8!3,$E"L6[HQ7/D\2B>"?;$0\$U M,O%?* @C(9!ABD*QL9@!VUF,TG TC3(ZYO$TC18HI5F8!HO\S=4+L0?,%DM1 M<5%E<%1"L8:7HITGSKG-:ZR&&0R+OT'/I9R_ M9!(P.N)CGH#EVAA#+T[SE5VT7R;E8N#>51\F>\^>$FEJRH^L[:EEXPE6=2RE M+*F;K<+]>)K JK-_*LME'^9GA$[&H0_* -G'/V>[/WFLP8OCR*,PES- E,M& M3CL),X /L40_':_6J-.MM'2*$(/3_DKL)1O9@_Z@VSX-G:/#OE/KS9ON_LQI MMX;.LB=U:U&_>W0]^R66N[7.TB&=1?/(B;KMAM1I SVUNF;7]F4HKS1KK6&S M?3B\GE5HJ0'3/4G&$O,(&$D*QY1:!IBO5%8Y8X&J2V*S@&6HZOO'S==Z#%%^ M5"]T)4_ QF6!0I-+>YE:4P XE6@K;9-=W;XD=BWMR 8Z.&PAHDAE*+B)0_L& MG+\8<&Z6;O-RP'D<@W4"(CONV6"H"::VMVI#8@^&LVS[L=VO[2^<(:&L? M#IJU$V*[_L)V/T6=T:<(VKV.FK.F"XCI_AE!^:%=LP%=G7ZG;:N.VYD[R\;< M'IV&G1'P&%U%318PA5&B8M-@X%H:OH8Z9*LSUO.0;;+[!YJN#S2\)%[:F.&$F/W9 >*Y),PBV M-+RV6M=R3_M.NZ-!O@K<$0 M>(#:E[;4&411,X?1"&HZF7?:HLWZ\CI\:KID!=PT,-$4#ZN$6M@+%!,KJDPU MPS(EW]-_%_@$H<+^):FZU_J458;)CO=N,S MRK[!Z6\(IZ_=?;\&IXTTG?+D MUP!5V_TJV8.3N3.RYW;;":'=J$,:6F?0F]MN?]@=?!H)N],9#*_;I'.G]G4! M=9'.LCZ'=X#'TP$ :PC>_+QYU!K9(^#KZ(0 C5= 5=:H;E'.P CE!E9U[F&/ M2 8V3$_79472/,5\ ]6[0%7A6-WQ-P/55=G-0'6#$TENK%N\4!C_4B2CB*OS MA+,K?;4ZR@7)N0):Q=FA?ZI;MRG^:7:O$ZU,R!/L&M'*BK'9EHDMV8"VR30N MB&/<7^TNJ^9S4Y0J[;GBC-GBM!R_C_R(IND6;X3FJ_H'B]&7ASM/"C- M:-MY7Y_6D0\\7V,T8-*L'\(W%\#UI/LR7TZU/6'2R K_%S+Q\OFUQ098!\PG MY^C3L#OZ.N_6AJIS=-JWCPZ'37=_:1_9LVY-9'/:2O>& 389@-D;KL^Z[2_:G;-GHDLT#R;<\E&.8V7## ID*AI,(:A8RE6N:5@2Y8\['N6 M;C'-)X9'2WO"Y 5I/ PLFDRY!GZ_/G@_IU1F^0C7TW'VOQ RI=-XVJ,F?"0 M.?(6R,]3NL G&X)AQ?/C'Z[E6X4I A+!O19N6P_UDGB6]86C/1$Y6#1%C ?0 M1'Y^6K%L+FEKE_':FGEQTJ>"=L2AA,;[?.E\71B:@=DP$2>OB*]2]66'SXRVS*B]=M'ISC[\>;_#TQ%>[1 Y-,<[;AQ(++8 ML;3NJZ.\JPZ*GMI*^/VIO&GU&]4E0U(8P9YJ6EBUP)BU#,O'FB\'*E4M F!Z M;R#QU6[$>&43V2I;FV%S\!VTW06,O16ZPQM9LGT 9AYQ7]Q%-8[SH-XTY7DI MX'65BRLN$ KS0%]Q,8282GE;T4(TGM]A)4!^#,S!DX2?A2F\!W!/Q[[ !.K[ MXIP_45A<=\1HPM(B"Y?=%5%4=NAY1/$RCI<10D^#2YMV_;FD/[)P7;OX8A(7 M?5Y->$3%)K(;5V%_\I"SLJ_?KK'9_1Y&:?U./[DP M^7L<>PFG0TP#:+1*HQE=I*7*\UP"\E2Z=[/SO1L9'Q5JE90E@EH\G499OF&P M";-JM1 !D;>;@>= M- 8T\04R]2D8G@+%&*!.Q*F G1!Z]0)ZDE4_"\@26/+W-#^V%Q70=LS!Y!,; M8Y B%8V7T3Y V^1BU\ TBE!^3=#Y%H,HO[EODN_W7+6ZNPHW@AD)DU \!I)% MZ<;XC*>9,%3S62S&.%U!'-0G+@3R<[;* *>KQ2;HV!3]04>3]Z@NCGQ/$;XD M$ZVB0;%)!)B:)N,P[4-S5%B[_="#SK"LLHS 0.< IT*>PO,CV: HZZ*.T#X9@K@ ] M#HX*Z%6&2D$8<9;;C4)%P;CR?+J>JRAS0Y=C5XP.'>42MRL49"S\IQGH2-%: M.O4&4"/*AX*C**1>&!65Y=6#A*\D9A<(3%:DACFE]PRMT,EK79^3G&_3SQ= MUU2LM]+9+%!DW>WM[#1!B)WT;A=-PS@L]QD/3MPR<,F=J+7(Q4_AKA/ ZJ_"W3*DOHZD/,EF#^( M@1KTA?9$6"+C8C:)LZEJ-*,H/\A\1X1"F(B+B)!NN(Y@B)J0N$H>L=5U;P\Y MENDN]^*WBH;*R@N'0[?J*L3CQI&S[YZTOG-;\MTGTZR3S_.OPK$XL;Y*U+SC M7B@F=?GRRR*"^/7Q:I;)E/G[NNUJ6C!^+B7R_1CC!H9?;KC$==75&PO0CR^0VS7+WE#FE8OMGXOJ[RZCKWZ, M*FFE8$HDDZ-/951/?-[[D5UHO_MT?./_]^1_H\7%5X\#5Z;_[J4[ 4Y#GR.Q MSA.*&-4;,+Q-C#?^?S$;0"1@'?1#'ES*SRJN DDV6$'Y9=9)*E[,%O"KGXVB MO?\'4$L#!!0 ( $(\75,4&B UU ( !,- 1 8V5R;BTR,#(Q,3 R M.2YX8DCFZD>J.WQ.,1QXT MEL6#XO.%04F4Q/NSJG]":;?#6!?/:'>&VY\(P;TH99BK57/5:DHU#Y,HBL/;+]-+[QIL?3,N[BK>ZYG*2O]6Z*9G1$/I3D&)BKLS M@&I2F8>NV#A*>@$BQB@^6QJ82)6? 2/+S R#I?BY)!EG'%(K> 9.THK#DVE# MU!S,5Y*#+@B%5T..&@@Y'7A>2&60. C<"A'W>KUP[2H+T$:WJ:3$^,7PHA#> M'[LACA/#6+BY7[8^,S)HVD]+E68!J"]QT M:"&037>5E%CS4%BLM@W(8*/-WUQXH:!NX1:B[8'A&_W/UY\"JUN_A7#!?Z-Z MA[ZR\XBGPV L[;U7WFW)QDWZ7V]&\3_BC#D3[$O@^)%?^1H3*6##WRH9+P?7;FW#[[ _3 MIY(W;-Y?H\8O4$L#!!0 ( $(\75,'EVQ,Y < .8W 5 8V5R;BTR M,#(Q,3 R.5]D968N>&ULW9M=;]LX%H;O^RN\WMMES$^1#)H,NFF["+8S#=H, M.M@;@Q^'CE!9"B2EDOIR]>O/P'0G_\^\.[R>O*W2RA;"=G M-9@6_.0V;Z\FGSPTGR>AKI:33U7].?]B$#KMOW167=_5^>*JG5!,R=/_UL?2 M.25"4,@Z91'/C$$:^X",#"08CCTQ[%^+8RN8$\%QI#-*$%>>(R,H1ERP 9" M<('VG19Y^?FX>[&F@4D<7-GT'T^F5VU[?3R;W=[>'JUL71Q5]6)&,6:S3>OI MNOEJI_TMZUL3K?6L_^_7IDT^U#!V2V9__/KNH[N"I4%YV;2F= \&HGG??OWB M8S5B=O_/V+3)CYO^^^\J9]H>SP^',/EFB^X3VC1#W25$*&+D:-7XZ>F+R>3> MVCOKN%DVN3+ZP(VUZYJ M"-]4OQER)TIT8SGVLRWN^J$;:05E=OJN>A"7?6536$L M%/W5N8=\_J9L\_;NO Q5O33K\_J_4:T<+;)KMQ%2]/1GL?%3GU=U?T@/[9QNIU5-V5;WYU5 M/L85)0G5D"%K8S3A5*NX (GO/,<4G/=2&SQ*6OF.B&<"?CQ'[\X#ECX/WN8% M_';3^67.C0@LB\E$"=^M-9E EIB %+%X+"Y*ZS#N!!!8"\< YTLI19+$TG!*JL$O+R]\U_TQ C^'< M7>HBG?HK[VMHFO6?;KAD[C(PV%"+N*==AO&XFX4*<1",9]Q+ F8$X@.FGPGM M5*?NDLY&(WT6W[ZO+ZO;6'" M>*"?6']>M%-I-VNCU61N^C$=B@1=K>NPM%49FEB8&WEV;!P\VT8T#5)/VKBYJZ.88Q.*MOQ?2 MW9:KWX<08TEF/0>)&0IR:T#M).V MMI[(.F^:&Z@?BZ/4$ 96(*FZ4S+62&29YDAX:;$00A&<5BG_2,%S(Y_FX@'^ M29M<'\'=Q,1R1ZB]S-L"YL'%M;G(-'(V%NX<*X444]V]3ZZ"I+PK -,B^!.+ M!\\WR84#/).VLBYKTYVS^WBWM%7,(]Y8D64> ?/T/H]8'C*$L1+4X+@^,VFE MUI:Y@R>YO_,&,";M5FWFU)N5NS+E OH;FXS%FLX*C[# "G$9@X7!')#)G*89 MP3C0Q.)JP.K!0TUVY0#;$;:EWBRA7L3)]I^ZNFVO8H*X-N7=W&,E.3<6^8S% M4L"8@ R-ZW#CJ7%64T8]&V%?:M#XP9,>R[$#P).VINYUG<7<7YOB/.;]U7_A M;JZ-\%J*@&R(JW,N2(:,B=J8"Q2KP*5/W-L8-/M,(*R*J@%_,FWK&WBX6)4MK-HW1;^&.IDVL'@XD[SG;C,L3+&^F;'* MFSFGECBF 6$(L=[3F47&:8(HMS16](XQFG:W]XG!$:%_Y[F$@4FP'[%J',_] ME,.4K_O8]:=TS)\\!9&06E\_>HA@G!#\K4RM,1G"C!# MWL2ZG%,LD'5>([E[(D/8IKX?/IB M?;E[Z9[V.GWQ?U!+ P04 " !"/%U3N1S$H<(+ "_; %0 &-E_WR_ M7'C?5;Y*LO3-F?\2GGDJ%9E,TJLW9[]?_@K(V<]O7[QX_3< _OC7EPOOETS< M+E5:>.>Y8H62WEU27'O?I%K]Y>D\6WK?LOROY#L#X&WUIO/LYB%/KJX++X"! MO_]J_BH6@F"M">""<( BQ@"%4@,6:U\S!*7/PI^N7G$<"JP% C0*?("(1(#A M *$0ZV8TEKHH JZ2-*_7I7_X6RE/)-;LNBAN7LUF=W=W+^]YOGB9 MY5>S ,)PMFU]MFE^WVA_%U:M?4KIK'KUL>DJ:6MHPOJS/WZ[^"JNU9*!)%T5 M+!5E!ZODU:IZ\B(3K*@\/ZK+ZVQ1_@MLFX'R*> '(/1?WJ_DV=L7GK>V(\\6 MZHO27OGW]R\?.KNDL[+%+%57Y2?[6>5))K\6+"\N&%<+H[Z*5CSZ=A^[&BS]](J?Z[+("K88X;)XZF9'\J)\ MXL(\VG13!CHPF%;];(;N':GJOE"I5.O1LA;:2^2;,_-H+E4R?Y\62?'P3LI< MK59FE"K4I_QSGGU/S*@^#Z1402R-\C#" #&( :-$ ^@3'" M(81B7CQ>VW.5 M@M^_;F54??7KZ,PBTZ*#6!,VN\W%4ZU;+MH*F*E=9;4CLY0MU>J&;=Y@U);3 M@G4";]=:O8W8G[Q*KI?EWE;PZ]E3B@/\78SFVF*JAF6B)FI13AZR?-^-3/1V MXPG*E4FDLF*EQ,NK[/O,A)B5<[7R 2@?5"P>#3QK?,+O\JUJEHLC]F]:S$1F M8MT4H/9)E/-*N_2*S.[B6-MJ1)R9CT.JW,R$6Q)JN60OV?T'::;#B4[6\[F/ MMTNN\CF5+):1&%(PDVQX5C;[ ?&+XJ<9N; MR'[ +Y-BH>8849\'"@&DI !(HP!0%)O93A1#@3 EF(9]QX+]X%/#OQ+E9=KS M@W_P?WI;N?VI;[AW'/0AGIR8;5L[K)#NRMN)XD:PT<#M2F.7U&YZ;6E (=Z_&.<7U+ ML)L=XU3=/DXXU-EFR@-*ZTZPD:MI,XUF 6UI8P_E-P.W^2)^GBV7M^FF$*_F M04AB"JD"FDD.4.Q#P#A4P#?/::[-'\+ZDMG:P]3PW(CTZBK[(]INXW%.!YMS M8E@M?;$"]F#N3M2V1QP-W8,)[?)[N*%K97V_5/E5DE[].\_NBFL3_(:E#W.J MXT!A[!N N9D#APP":A &4C %I50H$LJNR+;V,S6@-U5FJ]5;B_4V:FUK;[NU M?!7[(E2]*Y\'V!1! # MPW<$D! 2D$A)@*'@A" 5T="2^G7@B6+^YUK=_VRYWKC5%V1[#\8A]VCZ#JC6 MRQ_2\_ 4J5^P\DVH.8PY#2"$0@5;E7B9>+CA! RC4 M(B2&T+ WH+N!IX;F>?5CIQ'GE>KZ4UDSZSB/KA:V5M!V):J$WZU0*.! MUR9_%[G6UUVGH!]2D>4W65Y]K:U^]CW/;M,B?Z@N*QUQC@UMP)?4,*@" @@) M& ABRF/(90@%LIN9'NQO:FAN9FPUS3O[$3;*+;GMXWO?.>ZSN3G.U'>0D0[3 MXE[V#)@M'XX_\B2Z5[+-N76_M[D.+YO]))L_%TFJ_+F TI<:$A#[$0&(26$& M%>$#PE"(J8PHXM!I(]AN+Q,=2AXW-6T>>*58[U/JN@FL9FS?46.@7>.,%?9. MN>_^:G-B^-:O6M0?L^^K+;'.35^MC=WG%3K+E]6@4@;\4*CE:HX4A)0+"LJ[ M$0"*D :4Q!I(A)4(:*2Q[#VE[^YFHNCO2/7^K"[F2JWU,EBKL_TG#,/\&FN> M8&F5T]R@VXE!4X*6L*//!+I3:YL '&AMCW]YQ\[B\W66;O<_"![',HY]$%#? ME'L1!H R+H$?2HHCWT<1[OWS]'[PJ:%>Z?,J@=8;1QK&'6=ZB!TG)MG""2MX MNU)V0K81;#10N]+8Q;.SC0.4ZHHM-L7^/EG-P]@/8X)B$& F *)2 2(X-(^8 M8"'W(QF2WDS68T\.R5*>M_WMI51H47'W?>N!I+L;IR;2P@@[)-M3=B-R+]9X M0+8G4>.QHXG#.G?V7>7O^*K(F2CFF/M!Y$L&,(L10)!10"31@,2""L$C'/#> M/__6(D\-Q4J MI.A'FA#4>ZF[NYNI(6F4 K$CU5MK]2JQ_?D\X.MQ6)_'K1.3ZV:4%<;'?7!B M^D#8T0 _GMHN[3U:VZ/_SH229;A?%^S*3( #P9"2 $(4 $2"\L=EZH-00]_4 M7XTY3EJJ-/=[[$?."YS M5IZM]?5AR;/%'/* QAR:80'K<'UT".42 H$Q$E(R0H/>U;H6>6I#PD:3FGYAA9K# M@"BMH 0*8@00,G6:!N;;<1@(RID?8BQZG]O3VL/4('P\NV^MTC,RO5)G?QS; MC3R.Y6![3HRGM3-6H![,W@G8]HBC@7LPH5V #S=T!_G2O'5.!-,0LP@P%IGB M*0D%)!(*1$@%(=%F@DUZ%\_=P)/%MA1GSVKE57]$;1T8B\R#R3OAN)OI( JK M0*/#MRN_C;G:ZZZ[G;ZHJZ1DT=RQUM!NX1[F\K>)3?IG=I7,_Y@HS%8%((#/E+6\0Y I"$'$<4!$A M' NW'Y*;'@S?D;P3 M\\?L1VXFU;D;N:7I0, _9ZN"+?Z;W%2WV$C(:1 * 6)"A9D6^]6N"PRTCF+. M>"P#Y'8<;:V;J6.^%NL9M4YW,;4Z:PF[LU\C\][7*G?D6YT83GT][(\!OS6U M3O;;6SOBGZC5)>,+-0\I#96N3K C$" =8$"5DD"%& =2IA',5:*EO?\^;P\0A()P!@-@<2(1$I'0JK(KN3N]3!)$!^\C4JO MDND9G;9E=M_(OA5V@#WC%-?^SCA4U8[L!Q34_8@CU]*.A)IEM*NA^RG-[^_% MM?G\5+4R@PD)F58$J( ;F!%F@)CJ"81B+(C-W!G[VO:DYMT.IH;Q5J.W%6FY MO-5JXG&&AUIS8H0M77$ZL[DM]4'G-M<"CGYV/'J7PC]]9^/)[.WM;M<0=7. MCB*8%OSLJFC/9Y\]-%]F(=:KV>]'\ZJB]N8K$\;V<44_+X:GPI MG5,B!(6L4Q;QS!BDL0_(R$""X=@3P_Z]?&D%+*L2/D*8==]_?CQ> M$^D@5A /7+U:=)<71W4BP[V3D\+]!.W-!;R>-\7JHH3[<^<1PNMY]W?4>99@ MJCNQOZQ/L/BNQ46$)IWJK3Y))^[FZ:1NJA%__ M61H+97\V]U#D_>R'MFFC<6V.*152)2+*H!.Y.)'(T."1$CB=L5)2)]K^KVJ(MH#DSMH0<%/:,)-][ M )=N#YDA98)%&1'" J0[C/E1>J^)6]?[H5\/HYO5T4-,H>1>GHGN!Q^OT_AN MQ.+"Q#01>S9': &,&?W#KF6>MZT]H48:$? M.<;I)[ T9:_]S>%UT>2<6N*8!H0AA3^N,XN,TP11;JGSPC%&S2BW/Q*X/<>/ M<%D]#7Y;=OVMUF_KE2FJW!*?*4C1WAL.B%,L4OKT"F%FG529#$+J\;?[G;3M M.7V4NQ[?[YM@MQ,^/ZY"'5?W:1..6U@U.9.8",EEBG5$IRJ(8V2U9L@H[60Z M$-[Q"1CPE.Q!?*"[&P0F0G7+W+@OB,[2V%PZ*[P.!C%M.R@$0]:G2IH88WV0 MQ$LF1K'AH;0M)X$)/%=/ ...N/\48E'[=Y5_FQ9C.<NDX)3V7(2)Y%C(LJ%1D@G2Q+G40+]B>\&(TK#M!B^/*U?&BCCTHGY(SX*B^ MK-IX8PK.>ZD-GJ2H^(D2@TC#]XHTTX&^ M$QQZ7Y3PQ^7*0LRY2456EA*F$K[KRK%42Q,3D.)6!NF"22P$(@'SI%6CB*+I>&44(7=N#KD MI^('D23;*Y), ?1.,.;0^^2/YNZK@X?D+@.##;6(>]IE48\[QBO$03"><2\) MC.MB/2MZ$%/D7C%E+,"[Q)*C=/@AGM5754Z!4T:P1%YXACC!%&G!-0K&Z&1> MRIID0HY\%SR((6H?&;(AN+O$C[Z6^A!/8_VUJ!SDF6&4ZA0(4PQ,=E /J:C2 M&1*:V)0[E121](',47O(U/&P+Q+=#FMF]:4?Q<7?=VM25*49PF:3"5H M@F1(*480I',9!TL5F9 L:[*'==#P/G)EPBDE 0*KF.X MY2D@*BP06"(S[:DV,*Y=\E#:,#;L2T-U8QRW_6@U72U/S^OJ?C$FP3AM:%J" M92ZMRXVW2+GT04@(U!IF#:A1''@L<1@/]J6/.@K/+7/AK6ZK.X6 M7$U.%# 'U"&&9;?QB'N4EE<2@0],@SZSE(S%#@6B".@T_!3P=$)3#!6 #, MLU',>%[V,(;L2Z=T(HQWBRG'37,)\:$ME!K"P HD5;?)U1J)+-,<"2\M%D(H M@LW MJ=+RD"&,E: &IS6W&5>6KHD;QH)]:8ANCN2.A(-WU^[<5$OH=R,PELIE*SS" M BO$98II!G- )G.:9@3C0$<6HD]('4:(?>E[CL9U)_J=[U80EXG7_XWU57N> MCZ/$3X<.VB.U7QW,\RCM! MEJ.$7S3E<2J+KG^#FUP;X;44 =E DP&"9,B89 IS@6(5N/0C^UY/BAU&D'UI M@HY'=LO4.$P%L^^*YO>E6>8L9-('J5#2VR,>G$:&91)AR9D"HB66X_:%K8D; M1H5]Z8-NCN1D%'BU^ ')9->7S=X/[!\&=O;4X7U1F'*[OMY<)%Z.1Z7;\K6 D''>33(O!4YI-:/B1:<[?E_55,]+V[_-, M:_XS^CU$X.YNZ3ZZMVK?O/@?4$L! A0#% @ 0CQ=4\(E_%0L30 +UX% M !X ( ! &$Y.3%P&UL4$L! A0# M% @ 0CQ=4W45"<*]!P (ST !4 ( !%WL &-E